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Preamble
It is essential that the medical profession play a central role in
critically evaluating the evidence related to drugs, devices,
and procedures for the detection, management, or prevention
of disease. Properly applied, rigorous, expert analysis of the
available data documenting absolute and relative benefits and
risks of these therapies and procedures can improve the
effectiveness of care, optimize patient outcomes, and favor-
ably affect the cost of care by focusing resources on the most
effective strategies. One important use of such data is the
production of clinical practice guidelines that, in turn, canprovide a foundation for a variety of other applications, such
as performance measures, appropriate use criteria, clinical
decision support tools, and quality improvement tools.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
engaged in the production of guidelines in the area of
cardiovascular disease since 1980. The ACCF/AHA Task
Force on Practice Guidelines (Task Force) is charged with
developing, updating, and revising practice guidelines for
cardiovascular diseases and procedures, and the Task Force
directs and oversees this effort. Writing committees are
charged with assessing the evidence as an independent group
of authors to develop, update, or revise recommendations for
clinical practice.
Experts in the subject under consideration have been
selected from both organizations to examine subject-specific
data and write guidelines in partnership with representatives
from other medical practitioner and specialty groups. Writing
committees are specifically charged to perform a formal
literature review; weigh the strength of evidence for or
against particular tests, treatments, or procedures; and include
estimates of expected health outcomes where data exist.
Patient-specific modifiers, comorbidities, and issues of pa-
tient preference that may influence the choice of tests or
therapies are considered. When available, information from
studies on cost is considered, but data on efficacy and clinical
outcomes constitute the primary basis for recommendations
in these guidelines.
In analyzing the data and developing recommendations and
supporting text, the writing committee used evidence-based
methodologies developed by the Task Force that are de-
scribed elsewhere.1 The committee reviewed and ranked
evidence supporting current recommendations, with the
weight of evidence ranked as Level A if the data were derived
from multiple randomized clinical trials or meta-analyses.
The committee ranked available evidence as Level B when
data were derived from a single randomized trial or nonran-
domized studies. Evidence was ranked as Level C when the
primary source of the recommendation was consensus opin-
ion, case studies, or standard of care. In the narrative portions
of these guidelines, evidence is generally presented in chro-
nological order of development. Studies are identified as
observational, retrospective, prospective, or randomized
when appropriate. For certain conditions for which inade-
quate data are available, recommendations are based on
expert consensus and clinical experience and ranked as Level
C. An example is the use of penicillin for pneumococcal
pneumonia, where there are no randomized trials and treat-
ment is based on clinical experience. When recommendations
at Level C are supported by historical clinical data, appropri-
ate references (including clinical reviews) are cited if avail-
able. For issues where sparse data are available, a survey of
current practice among the clinicians on the writing commit-
tee was the basis for Level C recommendations and no
references are cited. The schema for Classification of Rec-
ommendations (COR) and Level of Evidence (LOE) is
summarized in Table 1, which also illustrates how the grading
system provides an estimate of the size as well as the certainty
of the treatment effect. A new addition to the ACCF/AHA
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 methodology is a separation of the Class III recommendations
to delineate whether the recommendation is determined to be
of “no benefit” or associated with “harm” to the patient. In
addition, in view of the increasing number of comparative
effectiveness studies, comparator verbs and suggested phrases
for writing recommendations for the comparative effective-
ness of one treatment/strategy with respect to another for
COR I and IIa, LOE A or B only, have been added.
The Task Force on Practice Guidelines makes every effort
to avoid actual, potential, or perceived conflicts of interest
that may arise as a result of industry relationships or personal
Table 1. Applying Classification of Recommendations and Level
■ 
*Data available from clinical trials or registries about the usefulness/efficacy
myocardial infarction, history of heart failure, and prior aspirin use. A recommen
Many important clinical questions addressed in the guidelines do not lend the
be a very clear clinical consensus that a particular test or therapy is useful o
†For comparative effectiveness recommendations (Class I and IIa; Level of Ev
direct comparisons of the treatments or strategies being evaluated.interests among the writing committee. Specifically, all mem-bers of the writing committee, as well as peer reviewers of the
document, are asked to disclose ALL relevant relationships
and those existing 24 months before initiation of the writing
effort. All guideline recommendations require a confidential
vote by the writing committee and must be approved by a
consensus of the members voting. Members who were
recused from voting are noted on the title page of this
document and in Appendix 1. Members must recuse them-
selves from voting on any recommendation to which their
relationship with industry and other entities (RWI) applies.
Any writing committee member who develops a new RWI
ence
rent subpopulations, such as gender, age, history of diabetes, history of prior
ith Level of Evidence B or C does not imply that the recommendation is weak.
to clinical trials. Even though randomized trials are not available, there may
ve.
A and B only), studies that support the use of comparator verbs should involveof Evid
in diffe
dation w
mselves
r effecti
idence:during his or her tenure is required to notify guideline staff in
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 writing. These statements are reviewed by the Task Force on
Practice Guidelines and all members during each conference
call and meeting of the writing committee and are updated as
changes occur. For detailed information about guideline
policies and procedures, please refer to the ACCF/AHA
methodology and policies manual.1 Authors’ and peer re-
viewers’ RWI pertinent to this guideline are disclosed in
Appendixes 1 and 2, respectively. In addition, to ensure
complete transparency, writing committee members’ compre-
hensive disclosure information—including RWI not pertinent
to this document—is available online as a supplement to this
document. Disclosure information for the ACCF/AHA Task
Force on Practice Guidelines is available online at www.
cardiosource.org/ACC/About-ACC/Leadership/Guidelines-
and-Documents-Task-Forces.aspx. The work of the writing
committee was supported exclusively by the ACCF and AHA
without commercial support. Writing group members volun-
teered their time for this effort.
The ACCF/AHA practice guidelines address patient pop-
ulations (and healthcare providers) residing in North Amer-
ica. As such, drugs that are not currently available in North
America are discussed in the text without a specific class of
recommendation. For studies performed in large numbers of
subjects outside of North America, each writing committee
reviews the potential impact of different practice patterns and
patient populations on the treatment effect and the relevance
to the ACCF/AHA target population to determine whether the
findings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to assist
healthcare providers in clinical decision making by describ-
ing a range of generally acceptable approaches to the diag-
nosis, management, and prevention of specific diseases or
conditions. These practice guidelines represent a consensus of
expert opinion after a thorough and systematic review of the
available current scientific evidence and are intended to
improve patient care. The guidelines attempt to define prac-
tices that meet the needs of most patients in most situations.
The ultimate judgment regarding care of a particular patient
must be made by the healthcare provider and patient in light
of all the circumstances presented by that patient. Thus, there
are circumstances in which deviations from these guidelines
may be appropriate. Clinical decision making should consider
the quality and availability of expertise in the area where care
is provided. When these guidelines are used as the basis for
regulatory or payer decisions, the goal should be improve-
ment in quality of care. The Task Force recognizes that
situations arise in which additional data are needed to better
inform patient care; these areas will be identified within each
respective guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if they are followed. Be-
cause lack of patient understanding and adherence may ad-
versely affect outcomes, physicians and other healthcare provid-
ers should make every effort to engage the patient’s active
participation in prescribed medical regimens and lifestyles.
The guidelines will be reviewed annually by the Task
Force and considered current until they are updated, revised,
or withdrawn from distribution. The executive summary and
recommendations are published in the Journal of the Amer-ican College of Cardiology, Circulation, and the Journal of
Cardiovascular Computed Tomography.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
1. Introduction
1.1. Methodology and Evidence Review
The recommendations listed in this document are, whenever
possible, evidence based. An extensive evidence review was
conducted for the period beginning March 2008 through April
2010. Searches were limited to studies, reviews, and other
evidence conducted in human subjects and published in English.
Key search words included, but were not limited to, African
Americans, Asian Americans, albuminuria, asymptomatic,
asymptomatic screening and brachial artery reactivity, athero-
sclerosis imaging, atrial fibrillation, brachial artery testing for
atherosclerosis, calibration, cardiac tomography, compliance,
carotid intima-media thickness (IMT), coronary calcium, coro-
nary computed tomography angiography (CCTA), C-reactive
protein (CRP), detection of subclinical atherosclerosis, discrim-
ination, endothelial function, family history, flow-mediated dila-
tion, genetics, genetic screening, guidelines, Hispanic Ameri-
cans, hemoglobin A, glycosylated, meta-analysis, Mexican
Americans, myocardial perfusion imaging (MPI), noninvasive
testing, noninvasive testing and type 2 diabetes, outcomes,
patient compliance, peripheral arterial tonometry (PAT), pe-
ripheral tonometry and atherosclerosis, lipoprotein-associated
phospholipase A2, primary prevention of coronary artery dis-
ease (CAD), proteinuria, cardiovascular risk, risk scoring,
receiver operating characteristics (ROC) curve, screening for
brachial artery reactivity, stress echocardiography, subclinical
atherosclerosis, subclinical and Framingham, subclinical and
Multi-Ethnic Study of Atherosclerosis (MESA), and type 2
diabetes. Additionally, the writing committee reviewed docu-
ments related to the subject matter previously published by the
ACCF and AHA, American Diabetes Association (ADA), Eu-
ropean Society of Cardiology, and the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC) 7. References selected and published in
this document are representative and not all-inclusive.
To provide clinicians with a comprehensive set of data,
whenever deemed appropriate or when published in the
article, data from the clinical trial will be used to calculate the
absolute risk difference and number needed to treat or harm;
data related to the relative treatment effects will also be
provided, such as odds ratio (OR), relative risk (RR), hazard
ratio (HR), or incidence rate ratio (IRR), along with confi-
dence interval (CI) when available.
The focus of this guideline is the initial assessment of the
apparently healthy adult for risk of developing cardiovascular
events associated with atherosclerotic vascular disease. The
goal of this early assessment of cardiovascular risk in an
asymptomatic individual is to provide the foundation for
targeted preventive efforts based on that individual’s pre-
dicted risk. It is based on the long-standing concept of
targeting the intensity of drug treatment interventions to the
severity of the patient’s risk.2 This clinical approach serves as
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 a complement to the population approach to prevention of
cardiovascular disease (CVD), in which population-wide
strategies are used regardless of an individual’s risk.
This guideline pertains to initial assessment of cardiovascular
risk in the asymptomatic adult. Although there is no clear age cut
point for defining the onset of risk for CVD, elevated risk factor
levels and subclinical abnormalities can be detected in adoles-
cents as well as young adults. To maximize the benefits of
prevention-oriented interventions, especially those involving
lifestyle changes, the writing committee advises that these
guidelines be applied in asymptomatic persons beginning at age
20. The writing committee recognizes that the decision about a
starting point is an arbitrary one.
This document specifically excludes from consideration
patients with a diagnosis of CVD or a coronary event, for
example, angina or anginal equivalent, myocardial infarction
(MI), or revascularization with percutaneous coronary inter-
vention or coronary artery bypass graft surgery. It also
excludes testing for patients with known peripheral artery
disease (PAD) and cerebral vascular disease. This guideline is
not intended to replace other sources of information on
cardiovascular risk assessment in specific disease groups or
higher-risk groups such as those with known hypertension or
diabetes who are receiving treatment.
1.2. Organization of the Writing Committee
The committee was composed of physicians and others
expert in the field of cardiology. The committee included
representatives from the American Society of Echocardi-
ography (ASE), American Society of Nuclear Cardiology
(ASNC), Society of Atherosclerosis Imaging and Preven-
tion (SAIP), Society for Cardiovascular Angiography and
Interventions (SCAI), Society of Cardiovascular Com-
puted Tomography (SCCT), and Society for Cardiovascu-
lar Magnetic Resonance (SCMR).
1.3. Document Review and Approval
This document was reviewed by 2 outside reviewers nomi-
nated by the ACCF and 2 outside reviewers nominated by the
AHA, as well as 2 reviewers each from ASE, ASNC, SAIP,
SCAI, SCCT, and SCMR, and 23 individual content review-
ers (including members from the Appropriate Use Criteria
Task Force, ACCF Cardiac Catheterization Committee,
ACCF Imaging Council, and ACCF Prevention of Cardio-
vascular Disease Committee). All reviewer RWI information
was collected and distributed to the writing committee and is
published in this document (Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACCF and AHA and endorsed by ASE,
ASNC, SAIP, SCCT, and SCMR.
1.4. Magnitude of the Problem of Cardiovascular
Risk in Asymptomatic Adults
Atherosclerotic CVD is the leading cause of death for both
men and women in the United States.3 Risk factors for the
development of atherosclerotic disease are widespread in the
U.S. population. In 2003, approximately 37% of American
adults reported having 2 risk factors for CVD. Ninety
percent of patients with coronary heart disease (CHD) have at
least 1 atherosclerotic risk factor.4 Approximately half of allcoronary deaths are not preceded by cardiac symptoms or
diagnoses.5 One aim of this guideline is to provide an
evidence-based approach to risk assessment in an effort to
lower this high burden of coronary deaths in asymptomatic
adults.
CVD was mentioned on the death certificates of 56% of
decedents in 2005. It was listed as the underlying cause of
death in 35.3% (864,480) of all deaths (2,448,017) in 2005 or
1 of every 2.8 deaths in the U.S.6 In every year since 1900
(except 1918), CVD accounted for more deaths than any
other major cause of death in the United States.6 It is
estimated that if all forms of major CVD were eliminated, life
expectancy would rise by almost 7 years.6 Analyses suggest
that the decrease in U.S. deaths due to CHD from 1980 to
2000 was partly attributable (approximately 47%) to
evidence-based medical therapies, and about 44% of the
reduction has been attributed to changes in risk factors in the
population.7 The estimated direct and indirect cost of CVD
for 2009 is $475.3 billion.6
CHD has a long asymptomatic latent period, which pro-
vides an opportunity for early preventive interventions. Ath-
erosclerosis begins in childhood and progresses into adult-
hood due to multiple coronary risk factors such as
unfavorable levels of blood lipids, blood pressure, body
weight and body fat, smoking, diabetes, and genetic predis-
position.8–10 The lifetime risk of CHD and its various
manifestations has been calculated for the Framingham Heart
Study population at different ages. In nearly 8000 persons
initially free of clinical evidence of CHD, the lifetime risk of
developing clinically manifest CHD (angina pectoris, MI,
coronary insufficiency, or death from CHD) at age 40 was
48.6% for men and 31.7% for women.11 At age 70, the
lifetime risk of developing CHD was 34.9% for men and
24.2% for women. The lifetime risk for all CVD combined is
nearly 2 of every 3 Americans.12 Thus, the problem is
immense, but the preventive opportunity is also great.
1.5. Assessing the Prognostic Value of Risk
Factors and Risk Markers
Many risk factors have been proposed as predictors of
CHD.13,14 New risk factors or markers are frequently identified
and evaluated as potential additions to standard risk assessment
strategies. The AHA has published a scientific statement on
appropriate methods for evaluating the predictive value of new
risk factors or risk markers.15 The scientific statement endorsed
previously published guidelines for proper reporting of observa-
tional studies in epidemiology16 but also went beyond those
guidelines to specifically address criteria for evaluation of
established and new risk markers. The current writing committee
endorses this scientific statement and incorporated these princi-
ples into the assessments for this guideline. The general concepts
and requirements for new risk marker validation and evaluation
are briefly reviewed to provide a basis for the assessments in this
document.
For any new risk marker to be considered useful for risk
prediction, it must, at the very least, have an independent
statistical association with risk after accounting for estab-
lished readily available and inexpensive risk markers. This
independent statistical association should be based on studies
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 that include large numbers of outcome events. Traditionally,
reports of novel risk markers have only gone this far,
reporting adjusted HRs with CIs and P values.17 Although
this level of basic statistical association is often regarded by
researchers as meaningful in prediction of a particular out-
come of interest, the AHA scientific statement called for
considerably more rigorous assessments that include analysis
of the calibration, discrimination, and reclassification of the
predictive model. Many of the tests reviewed in this guideline
fail to provide these more comprehensive measures of test
evaluation, and for this reason, many tests that are statistically
associated with clinical outcomes cannot be judged to be
useful beyond a standard risk assessment profile. In the
absence of this evidence of “additive predictive information,”
the writing committee generally concluded that a new risk
marker was not ready for routine use in risk assessment.
Calibration and discrimination are 2 separate concepts
that do not necessarily track with each other. Calibration
refers to the ability to correctly predict the proportion of
subjects within any given group who will experience
disease events. Among patients predicted to be at higher
risk, there will be a higher number of events, whereas
among patients identified as being at lower risk, there will
be fewer events. For example, if a diagnostic test or a
multivariable model splits patients into 3 groups with
predicted risks of 5%, 10%, and 15% within each group,
calibration would be considered good if in a separate group
of cohorts with similar predicted risks, the actual rates of
events were close to 5%, 10%, and 15%. Calibration is best
presented by displaying observed versus expected event
rates across quantiles of predicted risk for models that do
and do not include the new risk marker.
Discrimination is a different concept that refers to the
probability of a diagnostic test or a risk prediction instru-
ment to distinguish between patients who are at higher
compared with lower risk. For example, a clinician sees 2
random patients, 1 of whom is ultimately destined to
experience a clinical event. A diagnostic test or risk model
discriminates well if it usually correctly predicts which of
the 2 subjects is at higher risk for an event. Mathematically
this is described by calculating a C index or C statistic,
parameters that are analogous to the area under the ROC
curve. These statistics define the probability that a ran-
domly selected person from the “affected group” will have
a higher test score than a randomly selected person from
the “nonaffected group.” A test with no discrimination
would have a C statistic of 0.50 and a perfect test would
have a C statistic of 1.0. Throughout this document, C
statistic information is cited where available.
As an example of a risk marker that improves discrimina-
tion, MESA investigators found that the addition of coronary
artery calcium (CAC) scores to standard risk factors im-
proved the area under the ROC curve from 0.77 to 0.82
(P0.001).18 In contrast, a score based on 9 genes that code
for cholesterol levels added no predictive value over estab-
lished risk factors and family history.19 Similarly, a study
comparing the predictive capacity of conventional and newer
biomarkers for prediction of cardiovascular events derived a
C statistic of 0.760 for coronary events for the conventionalrisk factor model. Adding a number of newer biomarkers
changed the C statistic by only 0.009 (P0.08).20 Small
changes such as these in the C statistic suggest limited or
rather modest improvement in risk discrimination with addi-
tional risk markers.
Some investigators have called for evaluating the num-
ber of subjects reclassified into other risk categories based
on models that include the new risk marker.21 For example,
in a model of cardiovascular risk in a large cohort of
healthy women, the addition of CRP resulted in reclassi-
fication of a large proportion of subjects who were thought
to be at intermediate risk based on standard risk markers
alone.22 One problem with this approach is that not all
reclassification is necessarily clinically useful. If a patient
is deemed to be at intermediate risk and is then reclassified
as being at high or low risk, the clinician might find that
information helpful. It may not be known, however,
whether or not these reclassifications are correct for
individual subjects. Pencina and colleagues introduced 2
new approaches, namely “net reclassification improve-
ment” and “integrated with classification improvement,”
which provide quantitative estimates of correct reclassifi-
cations.23 Correct reclassifications are associated with
higher predicted risks for cases and lower predicted risks
for noncases.
1.6. Usefulness in Motivating Patients or
Guiding Therapy
In 1996 the American College of Cardiology Bethesda
Conference reviewed the concept of risk stratification, an
approach that is now standard for identifying the appropriate
degree of therapeutic or preventive interventions.2 Patients
deemed to be at low risk for clinical events are unlikely to
gain substantial benefits from pharmaceutical interventions
and therefore might best be managed with lifestyle modifi-
cations. Conversely, patients deemed to be at high risk for
events are more likely to benefit from pharmacologic inter-
ventions and therefore are appropriate candidates for inten-
sive risk factor modification efforts. Among patients at
intermediate risk, further testing may be indicated to refine
risks and assess the need for treatment. Although this model
is attractive and has been shown to be appropriate in certain
situations, there is no definitive evidence that it directly leads
to improved patient outcomes. Further research is clearly
needed, and it is appropriate to point out that the risk
stratification paradigm has not been subjected to rigorous
evaluation by randomized trials. Indeed, the impact of various
risk assessment modalities on patient outcomes is rarely
studied and not well documented in the few studies that have
been conducted.24
1.7. Economic Evaluation of Novel Risk Markers
The progressively rising costs of medical care have increased
interest in documenting the economic effects of new tests and
therapies. The most basic goal is to estimate the economic
consequences of a decision to order a new test. The ultimate
goal is to determine whether performing the test provides
sufficient value to justify its use.
A complete economic evaluation of the test has to account
for all the subsequent costs induced by ordering the test, not
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 just the cost of the test itself. The results of the test should
change subsequent clinical management, which might include
ordering follow-up tests, starting or stopping drug therapy, or
using a device or procedure. The costs of these subsequent
clinical management choices must be included in an
“intention-to-test” analysis of the economic consequences of
the initial decision to use the test. Ideally, the analysis should
be extended to account for clinical events that are either
averted or caused as a result of the strategy based on
performing the test.
An example of the economic consequences of testing will
illustrate the importance of these principles. Suppose a patient
with diabetes who has no cardiac symptoms undergoes a
computed tomography (CT) coronary angiogram, which re-
veals obstructive CAD but also leads to contrast-induced
nephropathy. Further suppose this patient has a follow-up
invasive coronary angiogram, undergoes insertion of a coro-
nary stent, and is treated for renal insufficiency. The costs of
all these “downstream events” should be included in any
economic assessment of the use of CCTA because they all
resulted from the initial decision to perform the test. Note that
the total costs of a “test strategy” may greatly exceed the cost
of the initial test itself.
The cost of any medical intervention has to be placed in the
context of the clinical benefits that the intervention provides.
In the example of the patient with diabetes, perhaps the
aggressive use of coronary revascularization actually ex-
tended life expectancy. Cost-effectiveness analysis provides a
formal framework with which to compare the clinical effec-
tiveness of an intervention (measured in patient-centered
outcomes such as length of life or quality of life) with the cost
of that intervention. Cost-effectiveness analysis has been
most commonly applied to the evaluation of new medical
therapies that directly improve clinical outcomes (eg, use of
bypass surgery to treat CAD). Diagnostic tests do not im-
prove clinical outcomes directly, however, and do so only
indirectly by changing clinical management decisions, which
in turn may improve clinical outcomes. Thus, determining the
cost-effectiveness of a diagnostic test depends on how effec-
tively the information is used and can be evaluated only in the
context of available treatments and how effective those
treatments are. A test that provides accurate risk information
about an untreatable disease is unlikely to be cost-effective
simply because clinical outcomes cannot be improved by its
use.
In general, testing strategies such as those assessed in this
document have not included evaluations of the cost and
cost-effectiveness of the tests. Therefore, although this gen-
eral guidance is offered to the reader as a caveat, the writing
committee was generally unable to find evidence to support
the cost-effectiveness of any of the tests and testing ap-
proaches discussed here. Where exceptions were identified,
cost-related information is included. In addition, for the
uncommon examples for which clinical outcomes of testing
strategies were assessed, the writing committee included that
evidence in the assessment of the value of the risk assessment
test.2. Approaches to Risk Stratification
2.1. General Approach to Risk Stratification
2.1.1. Recommendation for Global Risk Scoring
Class I
1. Global risk scores (such as the Framingham Risk Score
[FRS]) that use multiple traditional cardiovascular
risk factors should be obtained for risk assessment in
all asymptomatic adults without a clinical history of
CHD. These scores are useful for combining individual
risk factor measurements into a single quantitative
estimate of risk that can be used to target preventive
interventions.25 (Level of Evidence: B)
2.1.1.1. General Description
Prospective epidemological studies have established, primar-
ily in studies of people 40 years of age, that readily
measured and often modifiable risk factors are associated
with the development of clinical CHD in asymptomatic
individuals. There are robust prognostic data for each of the
“classic risk factors,” namely, cigarette smoking, cholesterol
levels, blood pressure levels, and diabetes. Data obtained
from the Framingham Heart Study and other population-
based cohorts have demonstrated that age, sex, cigarette
smoking, level of low-density lipoprotein (LDL) cholesterol
or total cholesterol, diabetes, and levels of blood pressure can
be combined in predictive models to estimate risk of fatal and
nonfatal CHD events.26 Beginning in the 1990s, a number of
global risk prediction instruments were introduced, based on
multivariable models that incorporated risk factor data and
clinical events.25–28 These instruments go beyond simple
demographics by taking into account modifiable risk markers
that are also appropriate evidence-based targets for preven-
tive interventions. Table 2 summarizes a sample of published
global risk score instruments.
Global risk assessment instruments, such as the FRS, are
considered valuable in medical practice because clinicians
and patients may not otherwise accurately assess risk. In
some survey studies, clinicians presented with scenarios were
found to overestimate the likelihood of a future major clinical
cardiovascular event.29 Other studies have suggested that
physicians may also underestimate risk.30–32 Failure to use
global quantitative risk instruments may result in physicians
inappropriately informing patients that they are at high risk
and inappropriately promoting therapeutic interventions of
modest or questionable benefit or, alternatively, inadequately
emphasizing risk when risk is actually present.
Global risk scores, although designed to estimate risk
across a continuous range from 0% to 100%, have most
commonly been advocated as a method by which patients can
be categorized in broad terms as “low risk,” “intermediate
risk,” and “high risk.” In general, patients are deemed to be
high risk if they are found to have a global risk estimate for
hard CHD events of at least 20% over 10 years. The threshold
for dividing low risk from intermediate risk is not uniform,
with some proposing a lower cutoff value of 6% risk over 10
years, whereas others use a value of 10% over 10 years.27,33,34
This document, unless otherwise noted, uses a lower cutoff
CAM, M
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 value of at least 10% and a higher cutoff of 20% to
designate intermediate risk.
The evidence with regard to global risk scores is most
appropriate for individuals 40 years of age. It is important
to note that there are limited data from Framingham and other
long-term observational studies on 10-year risk in young
adults; consequently, it is difficult to estimate 10-year risk in
young adults. This is due to the fact that 10-year risk in young
adults is very rarely impressively elevated, even in the face of
significant risk factors, and thus there are a limited number of
coronary events for calculating risk. As noted earlier in this
document, the long-term or lifetime risk may be substantially
raised by the presence of risk factors in young adults.
Although the earliest age at which these risk scores should be
used has not been rigorously established, the application of a
particular risk score or test should not detract from adherence
to a healthy lifestyle and identification of modifiable risk
factors beginning in childhood. Therefore, to direct attention
to the lifetime significance of coronary risk factors in younger
adults, the writing committee considered measurement of a
global risk score possibly worthwhile even in persons as
young as age 20.
2.1.2. Association With Increased Risk and Incremental
Risk of Additional Risk Factors
A number of global risk instruments have been devel-
oped.35 In the United States the best known is the FRS,
several variants of which have been published.25–28,34
Some include diabetes as a risk factor.25 The version
published with the National Cholesterol Education Pro-
gram Adult Treatment Panel (ATP III) report did not
include diabetes,27 which was considered to be a CHD risk
Table 2. Comparison of a Sample of Global Coronary and Cardio
Framingham SCORE
Sample size 5345 205 178
Age (y) 30 to 74; M: 49 19 to 80; M: 46
Mean follow-up (y) 12 13
Risk factors
considered
Age, sex, total
cholesterol, HDL
cholesterol,
smoking,
systolic blood
pressure,
antihypertensive
medications
Age, sex, total-
HDL cholesterol
ratio, smoking,
systolic blood
pressure
Endpoints CHD (MI and CHD
death)
Fatal CHD
URLs for risk
calculators
http://hp2010.
nhlbihin.net/
atpiii/calculator.
asp?usertypeprof
http://www.
heartscore.org/
Pages/welcome.
aspx
CHD indicates coronary heart disease; CVD, cardiovascular disease; HbA1C
protein; LDL, low-density lipoprotein; M, mean; MI, myocardial infarction; PROequivalent. Some versions of the FRS have focused onCHD death and nonfatal MI as endpoints, whereas a more
recent version focused on more comprehensive total car-
diovascular events.27,28,36 A European “SCORE” (System-
atic Coronary Risk Evaluation) was developed based on a
regression model derived from observations of 200,000
adults.37 This model differs from the Framingham model in
a variety of factors, including incorporation of age into a
time scale and consideration of geographic variability
within European countries as the calibration metric.35
Many of the multivariable coronary risk assessment func-
tions have been evaluated for predictive capability.38 In a
large number of different cohort studies, multivariable risk
equations typically yielded ROC areas approximately equal
to 0.80, indicating relatively high levels of predictive discrim-
ination. Data from the NHANES (National Health and
Nutrition Examination Surveys) prospective cohort study
were used to study how well a Framingham-type risk model
could predict first-time fatal and nonfatal CVD events.39 Risk
factors included in the model to assess risk of CVD were age,
systolic blood pressure, smoking status, total cholesterol,
reported diabetes status, and current treatment for hyperten-
sion. In women the risk model was useful for predicting
events, with a C statistic of 0.829. In men the results were
similar (C statistic, 0.78). Results such as these are typical for
a Framingham-like risk assessment model in most popula-
tions, but there has been concern that global risk scores
developed in one population may not be applicable to other
populations.24 The FRS has been validated in several external
populations, but in some cases it has required a “prevalence
correction” to recalibrate the scores to reflect lower popula-
tion prevalence of disease.25 Although global risk scores have
ar Risk Scores
ROCAM (Men) Reynolds (Women) Reynolds (Men)
24 558 10 724
65; M: 47 45; M: 52 50; M: 63
10.2 10.8
LDL cholesterol,
L cholesterol,
oking, systolic
od pressure,
ily history,
betes,
lycerides
Age, HbA1C (with
diabetes),
smoking, systolic
blood pressure,
total cholesterol,
HDL cholesterol,
hsCRP, parental
history of MI at
60 y of age
Age, systolic blood
pressure, total
cholesterol, HDL
cholesterol, smoking,
hsCRP, parental
history of MI at 60
y of age
/nonfatal MI or
dden cardiac
ath (CHD and
D combined)
MI, ischemic
stroke, coronary
revascularization,
cardiovascular
death (CHD and
CVD combined)
MI, stroke, coronary
revascularization,
cardiovascular death
(CHD and CVD
combined)
//www.chd-
kforce.com/
ronary_risk_
sessment.html
http://www.reynolds
riskscore.org/
http://www.reynolds
riskscore.org/
globin A1C; HDL, high density lipoprotein; hsCRP, high-sensitivity C-reactive
ünster Heart Study; and SCORE, Systematic Coronary Risk Evaluation.vascul
P
5389
35 to
10
Age,
HD
sm
blo
fam
dia
trig
Fatal
su
de
CV
http:
tas
co
as
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 is useful for discrimination, the focus on 10-year risk esti-
mates in clinical medicine makes many risk scores less useful
for clinical decision making in most younger male patients
and most women.40–42
Some large-scale investigations have suggested that nearly
90% of the population-attributable risk for CAD can be
ascribed to traditional biological and psychosocial risk fac-
tors.43 However, none of the current risk models, based only
on traditional risk factors such as the FRS, are able to
discriminate risk to an extent that would eliminate material
uncertainty of risk for individual patients being seen by
individual clinicians. Even in a global risk model such as the
FRS, which predicts risk with an area under the ROC curve of
as high as 80% in some studies,38 there is considerable
overlap in risk scores between people who are ultimately
found to be affected versus those found to be unaffected.
Hence, a number of investigators argue for ongoing discovery
and investigation of newer risk factors and predictive risk
markers to improve the ability of clinicians to discriminate
risk among their individual patients.20,44,45
In summary, a FRS, or a similar type of multivariable
predictive score based on traditional cardiovascular risk
factors, is highly predictive of cardiovascular events. Given
the familiarity of health professionals and the general public
with the traditional risk factors and the proven efficacy of
interventions for modifiable factors in these models, the
writing committee agreed with many previous clinical prac-
tice guidelines that a “Framingham-like” risk score should be
the basic risk assessment strategy to use for all asymptomatic
adult patients.46–53 Additional risk markers should be as-
sessed for their ability to improve on risk assessment beyond
prediction from the multivariable global risk score. The
writing committee felt that it is reasonable to advocate global
risk score measures coincident with guideline-supported mea-
surements of blood pressure or cholesterol beginning at age
20 and then every 5 years thereafter.27 The writing committee
also acknowledged that some investigators advocate a shift in
the risk assessment focus to ‘lifetime risk” of CHD, but to
date, evidence is sparse on how best to incorporate estimates
of lifetime risk into clinical management.11 Another approach
to the long-term risk estimation problem in younger adults
was recently presented by the Framingham Study investiga-
tors as the “30-Year Risk of Cardiovascular Disease”.54
2.2. Family History and Genomics
2.2.1. Recommendation for Family History
Class I
1. Family history of atherothrombotic CVD should be
obtained for cardiovascular risk assessment in all
asymptomatic adults.22,55 (Level of Evidence: B)
2.2.1.1. Association With Increased Cardiovascular Risk
and Incremental Risk
A family history of premature (early-onset) atherothrombotic
CVD, defined most often as occurring in a first-degree male
relative 55 years of age or in a first-degree female relative
65 years of age, has long been considered a risk factor for
CVD. Even a positive parental history that is not prematureincreases the risk of CVD in offspring.56 The importance of
family history is not surprising because the risk factors for
CVD, including hypertension, dyslipidemia, diabetes, obe-
sity, and smoking behavior, are in part heritable.19,57–62 In
addition, lifestyle habits such as diet, exercise, and smoking
are in part learned behaviors influenced by family patterns.
However, studies examining parents, siblings, twins, and
second-degree relatives have demonstrated that the 1.5- to
2.0-fold RR of family history persists even after adjusting for
coexistent risk factors.56,63–66 The risk associated with a
positive family history for CVD is observed in individuals of
White European, African American, Hispanic, and Japanese
descent.67–69 The strength of the risk for an individual
increases with younger age of onset, increasing numbers of
relatives affected, and the relative’s genealogical proximi-
ty.56,63,66,70 Although the prevalence of a positive family
history ranges from 14% to 35% in the general population,
almost 75% of those with premature CHD have a positive
family history, underscoring opportunities for prevention.71,72
The reliability of self-reported family history is imper-
fect.71,73 To address recall bias, investigators from the Fra-
mingham Study used validated parental data and reported that
although the negative predictive value for reports of prema-
ture MI and CHD death was superb (90%), the positive
predictive value for validated events was only fair (28% to
66%).73 Similarly, the Health Family Tree Study found that
the positive predictive value of a positive family history of
CHD was 67%, but the negative predictive value was excel-
lent at 96%.70,71 The sensitivity of self-reported family history
is 70%.71,73 In addition, there has been increasing attention
to improving the collection of family history through stan-
dardized questionnaires and online resources.74
Family history modestly improves risk stratification. In the
Framingham Heart Study, the inclusion of a positive family
history improved ability to predict CVD (the multivariable
model C statistic [ROC] increased from 0.82 to 0.83). Family
history appeared to aid in reclassifying individuals and was
most useful in persons at intermediate risk (third and fourth
multivariable predicted risk quintile) of CVD.63,64
2.2.1.2. Usefulness in Motivating Patients or
Guiding Therapy
The ability of family history of CVD to motivate patients is
not definitively established. Some studies have reported that
persons with a positive family history of CHD were more
motivated to modify their risk factors.75 In the CARDIA
(Coronary Artery Risk Development in Young Adults) study,
however, young adults did not self-initiate or modify their
CVD risk factors after a change in family history of heart
attack or stroke.76 Intensive interventions targeting those with
a positive family history of CHD can improve risk factors;
however, the sustainability of such interventions and their
influence on CHD events has been more difficult to prove. For
instance, a randomized study of black patients with a family
history of premature CHD demonstrated that intensive
community-based multiple risk factor intervention resulted in
significant reductions in global CHD risk (improvements in
cholesterol and blood pressure) compared with an enhanced
primary care group.77 However, the sustainability of such
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 efforts was disappointing; 5 years after completion, the
previously observed improved risk factor profile of the
intensive community-based group was no longer apparent
and there was no significant difference in events.78
2.2.2. Genotypes: Common Genetic Variants for Coronary
Heart Disease
2.2.2.1. Recommendation for Genomic Testing
Class III: No Benefit
1. Genotype testing for CHD risk assessment in asymp-
tomatic adults is not recommended.79,80 (Level of Evi-
dence: B)
2.2.2.2. Association With Increased Cardiovascular Risk
and Incremental Risk
CHD is typically due to the complex interplay between
environmental factors and multiple common genetic variants
(minor allele frequency 5%) with small or very modest
effects (OR typically 1.2 to 1.5, and rarely 2.0).81 The first
widely replicated genetic variant for CHD was discovered by
a genomewide association study on chromosome 9p21.3.82–84
The 1.3- to 2.0-fold increased risk for MI observed with
single nucleotide polymorphisms (SNPs) from the 9p21.3
genomic region has been observed in persons of various
ethnicities, including European, Asian, and Hispanic descent,
but thus far it has not been replicated in African Americans,
which may relate to patterns of haplotype diversity in the
genomic region.82–87 The mechanisms underlying the 9p21.3
association with CHD remain unclear, although the variants
are adjacent to CDKN2A, ARF, and CDKN2B, which are
genes thought to regulate senescence and apoptosis.88 Vari-
ants tested in the 9p21.3 region (rs10757274, GG versus AA)
were associated with a HR for incident CHD of 1.6 for
incident CHD in men participating in the NPHS II (North-
wick Park Heart Study II).89 The addition of the genotype to
a model based on traditional CVD risk factors did not
significantly improve risk discrimination (area under the
ROC, 0.62 [95% CI 0.58 to 0.66] to 0.64 [95% CI 0.60 to
0.68]; P0.14). However, the genotype resulted in better
model fit (likelihood ratio, P0.01) and shifted 13.5% of the
men into a more accurate risk category.89
In the Women’s Genome Health Study (n22,129), an
SNP at chromosome 9p21.3 was associated with an increased
hazard for incident CVD; however, the SNP did not enhance
model discrimination (C index, 0.807 to 0.809) or net
reclassification when added to the Reynolds risk score, which
includes family history.79 In another study, investigators
reported that a genome score including 9 SNPs associated
with serum lipid levels was associated with an increased risk
of CVD events, but the score did not improve model
discrimination (ROC, 0.80 for the model with and without the
score). Furthermore, investigators reported that having a
parent or sibling with a history of MI conferred a 50%
increased risk of incident cardiovascular events (HR 1.52;
95% CI 1.17 to 1.97; P0.002) in a model including the
genotype score.90 Family history may integrate the complex-
ity of interacting genomic and environmental factors shared
by family members. Many other SNPs have been reported asrisk markers for future CHD events. Given the very small OR
and the small incremental risk information of the individual
polymorphisms, the writing committee judged that genomic
tests for CHD risk currently offer no proven benefit in risk
assessment when added to a global basic risk score such as
the FRS.
2.2.2.3. Usefulness in Motivating Patients or
Guiding Therapy
Studies assessing whether genotype testing enhances motiva-
tion and success with adherence to recommended lifestyle
and medical therapies demonstrate mixed results.80,91 Smok-
ers given scenarios of genotype testing information report
more motivation to quit but lower levels of perceived control
and similar success with smoking cessation at 1 year.92,93 In
another study, persons who agreed to receive genotype data
(GSTM1 SNP) were more likely to abstain from cigarette
smoking at 12-month follow-up than those who declined the
test, regardless of whether they tested positive or negative for
the risk SNP.94
No data are available as to whether the results of genotype
testing alter management or improve outcomes for prevention
of CHD.92,95 Despite the uncertainty about the clinical impli-
cations of most genotypic markers for CHD, there is wide-
spread direct-to-consumer marketing of these tests.95 A con-
cern is that advertisements and genetic information provided
by for-profit genomic testing services may overstate claims
and confuse or frighten consumers. In addition, regulation of
the companies and provision for genetic counseling is spo-
radic.95 Thus, the writing committee was aware of no benefit
of genotype testing, and given the limited benefit in terms of
risk assessment, the writing committee concluded that these
types of tests should not be done at this time.
2.3. Lipoprotein and Apolipoprotein Assessments
2.3.1. Recommendation for Lipoprotein and Apolipoprotein
Assessments
Class III: No Benefit
1. Measurement of lipid parameters, including lipopro-
teins, apolipoproteins, particle size, and density, be-
yond a standard fasting lipid profile is not recom-
mended for cardiovascular risk assessment in
asymptomatic adults.96 (Level of Evidence: C)
2.3.2. Assessment of Lipoprotein Concentrations, Other
Lipoprotein Parameters, and Modified Lipids
Beyond the standard fasting lipid profile (total cholesterol,
high-density lipoprotein (HDL) cholesterol, LDL cholesterol,
and triglycerides), additional measurements of lipid parame-
ters or modified lipids have been proposed to extend the risk
factor–cardiovascular prediction relationship. Each LDL par-
ticle contains 1 molecule of apolipoprotein B (often referred
to as ApoB); thus, the concentration of ApoB directly reflects
LDL particle numbers. The relationship between apolipopro-
tein A (often referred to as ApoA) and HDL is less direct.
Several techniques directly measure lipid particle numbers or
their size distribution. All lipid particles (eg, LDL or HDL)
are present in the circulation in a range of sizes. Oxidative
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 modification of lipid particles occurs and appears to influence
their atherogenic potential.
Non-HDL cholesterol, meaning cholesterol transported in
LDL and very-low-density lipoprotein, reflects the total
concentration of atherogenic particles, is closely related to
particle number, and is simply calculated as the difference
between total cholesterol and HDL-cholesterol blood concen-
trations. Particle size is similarly closely related to HDL and
triglyceride concentrations. High concentrations of triglycer-
ides lead to triglyceride enrichment of LDL or HDL. Subse-
quent particle modification by hepatic lipase leads to reduc-
tion of particle size and increased density, properties
associated with heightened atherogenic potential. Treatment
guidelines for the consideration of pharmacotherapy and the
therapeutic targets for non-HDL cholesterol are 30 mg/dL
higher than the thresholds for LDL cholesterol.27
2.3.3. Risk Prediction Relationships Beyond
Standard Risk Factors
Many so-called “advanced lipid measures” of the type dis-
cussed above, particularly apolipoprotein concentrations and
particle number, have been shown by some, but not all,
studies to be associated with cardiovascular outcomes com-
parable to standard lipid concentrations.43,97 For example, the
EPIC-Norfolk (European Prospective Investigation into Can-
cer and Nutrition) study among apparently healthy individu-
als showed a 34% increased odds for future CHD associated
with the highest quartile of LDL particle number after
controlling for the FRS.97 However, this was similar to
non-HDL cholesterol (38% increased odds); thus, no relative
benefit of particle number determinations was found. A recent
systematic review observed that no study has reported the
incremental predictive value of LDL subfractions beyond that
of traditional cardiovascular risk factors, nor evaluated their
independent test performance (for example, sensitivity and
specificity).96 Although the distribution of advanced lipid
measures is different in men and women (and is also related
to menopausal status), the outcome relationships are present
for both men and women in similar magnitude.98,99
Two studies have specifically evaluated the predictive
performance of ApoB or nuclear magnetic resonance LDL-
particle concentration for risk reclassification of asymptom-
atic individuals compared with standard lipids. In the Fra-
mingham Heart Study, little additional risk information was
obtained from ApoB or ApoB/A-1 ratio compared with the
total/HDL-cholesterol ratio.100 Thus, evidence that these
more “advanced” lipid measures improve predictive capacity
beyond standard lipid measurements is lacking.101
The role of lipoprotein(a) [Lp(a)] in risk assessment has
received attention as a potential additional risk marker. In the
Emerging Risk Factors Collaboration, circulating concentra-
tion of Lp(a), a large glycoprotein attached to an LDL-like
particle, was assessed for its relationship with risk of major
vascular and nonvascular outcomes. Long-term prospective
studies that recorded Lp(a) concentration and subsequent
major vascular morbidity and/or cause-specific mortality
published between January 1970 and March 2009 were
identified through electronic and other means.102 Information
was available from 126 634 participants in 36 prospectivestudies and spanned 1.3 million person-years of follow-up.
Lp(a) concentration was weakly correlated with several
conventional vascular risk factors and highly consistent
within individuals over several years. In the 24 cohort studies,
the risk ratio for CHD was 1.13 per standard deviation for
higher Lp(a) (95% CI 1.09 to 1.18) after adjustment for age,
sex, lipid levels, and other conventional risk factors. The
corresponding adjusted risk ratios were 1.10 (95% CI 1.02 to
1.18) for ischemic stroke, 1.01 (95% CI 0.98 to 1.05) for the
aggregate of nonvascular deaths, 1.00 (95% CI 0.97 to 1.04)
for cancer deaths, and 1.00 (95% CI 0.95 to 1.06) for
nonvascular deaths other than cancer. This study demon-
strated that there are continuous, independent, but modest
associations of Lp(a) concentration with risk of CHD and
stroke. As with previous individual reports, associations were
only modest in degree, and detailed information on incremen-
tal risk prediction beyond traditional risk factors is still
lacking. There have also been, and continue to be, con-
cerns about measurement and standardization of measure-
ment of Lp(a) in clinical settings.103 The writing commit-
tee therefore concluded that measurement of Lp(a) did not
merit consideration for cardiovascular risk assessment in
the asymptomatic individual.
2.3.4. Usefulness in Motivating Patients or
Guiding Therapy
Additional lipid measures, beyond the standard lipid profile,
vary in their interassay agreement, laboratory standardization,
and established reference ranges and are generally limited by
the absence of clear thresholds for initiation of treatment,
therapeutic targets, or unique treatments beyond those already
recommended by lipid treatment guidelines directed by the
standard lipid profile.104
2.3.5. Evidence for Improved Net Health Outcomes
There is no evidence that the assessment of additional lipid
parameters leads to improved net health outcomes, and thus
the cost-effectiveness of these measures cannot be assessed.
2.4. Other Circulating Blood Markers and
Associated Conditions
2.4.1. Recommendation for Measurement of
Natriuretic Peptides
Class III: No Benefit
1. Measurement of natriuretic peptides is not recommended
for CHD risk assessment in asymptomatic adults.105
(Level of Evidence: B)
2.4.1.1. General Description
Atrial natriuretic peptide, B-type natriuretic peptide, and their
precursors (N-terminal-proatrial natriuretic peptide) are
emerging markers of prevalent CVD. Natriuretic peptides are
released from the myocardium in response to increased wall
stress and have been shown to be helpful in the diagnosis of
heart failure among symptomatic patients, as well as having
prognostic value in patients with established heart failure.
Levels of natriuretic peptides have also been demonstrated to
be markers of prognosis in patients with either acute coronary
syndromes or stable CAD.
eptide;
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 Recent studies have examined whether natriuretic peptides
also predict the development of CVD in the asymptomatic,
healthy adult population. The evidence from several prospec-
tive cohort investigations (Table 3) suggests that higher levels
of natriuretic peptides predict the development of incident
CVD, including heart failure, stroke, and atrial fibrillation.
There is some evidence that natriuretic peptides are stron-
ger predictors of the development of heart failure than of
incident coronary events,106–108 and other studies suggest that
Table 3. Cardiovascular Disease Risk Assessment for B-Type Na
Study Name Population N Age
Framingham,
MA108
Ambulatory adults,
3.4% with prior MI
3,352 59
Copenhagen,
Denmark109
Random sample of
general population
without CVD
626 67.9
Glostrup,
Denmark107
General population
without CVD
1,994 30 to 60
Rancho Bernardo,
CA110
General population
without CVD
805 77
Glasgow,
Scotland111
Random sample of
general population,
some with
prevalent CHD
1,252 50.4
Kuopio, Finland112 Kuopio Ischemic
Heart Disease Risk
Factor Study,
longitudinal
population-based
sample of men
905 55.8 (46 to
Olmsted County,
MN106
General population
without congestive
heart failure or
renal failure
2,042 62 10
Malmo, Sweden20 General population
without CVD
5,067 58
Uppsala,
Sweden113
General population
without CVD
661 71
BNP indicates B-type natriuretic peptide; CHD, coronary heart disease; CV, c
NT, N-terminal; proANP, atrial natriuretic peptide; proBNP, B-type natriuretic ptheir prognostic value is attenuated after adjustment forechocardiographic measures such as left ventricular mass and
left ventricular diameter. The mechanism for these associa-
tions is as yet undetermined, and it is possible that natriuretic
peptides are markers of left ventricular hypertrophy (LVH) or
subclinical myocardial damage from hypertension, ischemia,
or both.
Most prospective cohort studies (Table 3) report that
natriuretic peptides predict prognosis and do so independent
of other cardiac risk markers. Although these cohort studies
ic Peptide
Follow-Up
(y) Event Main Findings
5.2 Major CVD (CHD death,
MI, stroke, heart
failure, coronary
insufficiency)
CHD death: HR 1.27/SD of
NT-proANP, HR 1.41/SD
of BNP; major event: HR
1.28/SD of NT-proANP,
1.30/SD of BNP
5.0 Death; major CVD
(CHD death, MI,
stroke, heart failure,
unstable angina, TIA)
Death: HR 1.43/SD of NT-
proBNP; CV event: HR
1.92/SD (all
multivariable adjusted)
9.4 CV events (CVD death,
MI, stroke)
CV events: HR 1.58/SD
NT-proBNP; evidence of
interaction with age
6.8 Death; CV death Death: HR 1.74/SD of NT-
proBNP; CV events: HR
1.85/SD of NT-proBNP
(multivariable adjusted)
4.0 All-cause mortality Death: HR 2.2 for BNP
17.9 pg/mL
(multivariable adjusted
for age, sex, prior CHD)
10 Death, CV death, CHD
death
Multivariable-adjusted
HR/SD change:
proANP proBNP
1.35 1.26
1.48 1.41
1.52 1.44
5.6 All-cause mortality Mortality somewhat assay
dependent (Shionogi,
Biosite, NT-proBNP),
adjusted mortality
ranged from HR 1.63 to
1.39, somewhat
attenuated if adjusted
for echocardiographic
measurements
12.8 CV events (CV death,
MI, stroke)
Multivariable-adjusted HR/
SD change for BNP
1.22, C index
improvement,
0.004 (P0.12)
10 CV death Multivariable-adjusted HR/
SD change for NT-pro-
BNP 1.58, C index
improvement,
0.034 (P0.20)
cular; CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction;
SD, standard deviation; and TIA, transient ischemic attack.triuret
65)
ardiovassuggest that natriuretic peptide levels convey prognostic
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 information, the value of that information has not yet been
rigorously evaluated by use of the C index or measures of risk
reclassification.105 Consequently, the value of natriuretic
peptide measurement in the assessment of cardiovascular risk
among asymptomatic adults free of CAD or heart failure is
not definitively known. Because of the absence of such data,
the writing committee does not recommend measurement of
natriuretic peptides for risk assessment in the asymptomatic
adult.
2.4.1.2. Usefulness in Motivating Patients or
Guiding Therapy
There have been no studies evaluating whether natriuretic
peptides have value in motivating healthy patients, guiding
treatment, or improving outcomes (there is some evidence on
these points in populations of patients with heart failure but
not in asymptomatic adults).
2.4.2. Recommendations for Measurement of
C-Reactive Protein
Class IIa
1. In men 50 years of age or older or women 60 years of
age or older with LDL cholesterol less than 130 mg/dL;
not on lipid-lowering, hormone replacement, or immu-
nosuppressant therapy; without clinical CHD, diabe-
tes, chronic kidney disease, severe inflammatory con-
ditions, or contraindications to statins, measurement of
CRP can be useful in the selection of patients for statin
therapy.114 (Level of Evidence: B)
Class IIb
1. In asymptomatic intermediate-risk men 50 years of age
or younger or women 60 years of age or younger,
measurement of CRP may be reasonable for cardio-
vascular risk assessment.22,115 (Level of Evidence: B)
Class III: No Benefit
1. In asymptomatic high-risk adults, measurement of
CRP is not recommended for cardiovascular risk
assessment.116 (Level of Evidence: B)
2. In low-risk men younger than 50 years of age or
women 60 years of age or younger, measurement of
CRP is not recommended for cardiovascular risk
assessment.22,115 (Level of Evidence: B)
2.4.2.1. Association With Increased Cardiovascular Risk and
Incremental Risk Prediction
Inflammation is considered to be central to the pathogenesis
of atherosclerosis, and numerous inflammatory biomarkers
have been evaluated as risk factors or risk markers for CVD.
The most intensively studied inflammatory biomarker asso-
ciated with CVD risk is high-sensitivity CRP (hsCRP). CRP
is associated with an adjusted increased risk for development
of other CVD risk factors, including incident diabetes, inci-
dent weight gain, and new-onset hypertension.117–119 Inter-
ventions that improve CVD risk factors, such as exercise,
weight loss, smoking cessation, statins, and antihypertensive
treatments, are associated with lowering of CRP.120–124 CRP
concentrations are fairly constant and repeatable overtime.125,126 In the JUPITER (Justification for the Use of
Statins in Prevention: an Intervention Trial Evaluating Rosu-
vastatin) study participants randomly assigned to placebo,
intraclass correlation was 0.54 (95% CI 0.53 to 0.55), which
was similar to blood pressure and LDL cholesterol.127 Prior
guidelines have recommended measuring CRP twice, partic-
ularly in persons with intercurrent illness if elevated when
first measured.128
A meta-analysis of 20 observational studies (both
prospective and case-control) demonstrated that CRP lev-
els are associated with incident CHD, with an adjusted
odds ratio (comparing persons in the top versus bottom
third) of 1.45 (95% CI 1.25 to 1.68).129 CRP levels have
been associated with incident CHD in both men and
women and persons of European, Japanese, and American
Indian descents.22,130 –132 CRP is also associated with other
forms of CVD, including incident stroke, PAD, heart
failure, atrial fibrillation, sudden death, and all-cause
mortality.133–137 Despite consistent evidence that CRP
levels above the population median value are associated
with increased risk of CHD, it has not been determined
whether CRP is causally related to CHD.138 –142
CRP modestly improved risk prediction of CVD endpoints
in some studies beyond that accounted for by standard CVD
risk factor testing.143 However, after accounting for standard
CVD risk factors in many studies, model discrimination (area
under the ROC) had no or minimal improvement.144,145 As
noted earlier in this guideline, statisticians recently proposed
that measures of reclassification should be used to evaluate
new biomarkers in addition to metrics of test discrimination,
calibration, and other standard approaches to evaluate new
markers. Data from the Physicians’ Health Study and Fra-
mingham Heart Study have shown that CRP measurements
improve reclassification of an individual’s risk beyond stan-
dard risk prediction models.115,145 However, a meta-analysis
including data from the NPHS II and the Edinburgh Artery
Study concluded that the ability of CRP to reclassify risk
correctly was modest and inconsistent.144 As with most new
biomarker tests, whether knowledge of CRP levels improves
patients’ motivation to adhere to CHD lifestyle or pharma-
cological treatments is unknown.
Recent clinical trial data provided evidence that measure-
ment of CRP in highly preselected patients may have impor-
tant clinical implications. The JUPITER trial was a random-
ized, double-blind, placebo-controlled trial of the use of
rosuvastatin (20 mg/d) versus placebo in the primary preven-
tion of CVD events in men and women (n17,802) without
diabetes with LDL cholesterol 130 mg/dL and CRP 2
mg/L.146,147 After a median follow-up of 1.9 years, rosuvas-
tatin was associated with a significant reduction in the
primary endpoint of cardiovascular events. The HR for
rosuvastatin versus placebo was 0.56 (95% CI 0.46 to 0.69;
P0.00001), and the event rate was 0.77 versus 1.36 per 100
person-years of follow-up.147 The reduction in endpoints was
consistent across prespecified subgroups, including men and
women, older and younger persons, whites and non-whites,
and persons at higher and lower risk as measured by the
FRS.147 Within JUPITER, 17 men and 31 women would need
to be treated for 5 years to prevent the endpoint of MI, stroke,
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 revascularization, or death.148 For persons at low risk (FRS
10), 37 persons would need to be treated for 5 years to
prevent the same previous endpoints.148
The JUPITER trial leaves a number of questions unan-
swered about use of CRP levels in cardiovascular risk
assessment. Specifically, JUPITER was not a trial of CRP,149
because persons with unknown or low CRP concentrations
were not studied. Cost-effectiveness of CRP testing in an
asymptomatic population, beyond the specific patient popu-
lation of JUPITER, has not yet been studied.
2.4.3. Metabolic: Hemoglobin A1C
2.4.3.1. Recommendation for Measurement of
Hemoglobin A1C
Class IIb
1. Measurement of hemoglobin A1C (HbA1C) may be
reasonable for cardiovascular risk assessment in
asymptomatic adults without a diagnosis of diabe-
tes.150–155 (Level of Evidence: B)
2.4.3.2. General Description
HbA1C is a blood test useful for providing an estimate of
average glycemic control over several months. The test has
been shown to be predictive of new-onset diabetes.156 A
systematic review and a recent international expert committee
have suggested that HbA1C might be effective to screen for
the presence of diabetes.157,158 The ADA has endorsed the use
of HbA1C to diagnose diabetes (HbA1C 6.5%) and to
identify persons at increased risk for diabetes (HbA1C, 5.7%
to 6.4%).158
2.4.3.3. Association With Cardiovascular Risk in Persons
Without Diabetes
In 1 study, in individuals without established diabetes, for
every 1 percentage point higher HbA1C concentration,
there was an adjusted 40% higher risk of CHD
(P0.002).150 HbA1C was associated with an increased
risk of incident stroke in the Japanese.159 Whether or not
HbA1C improves CVD risk discrimination and reclassifi-
cation is less certain. Some studies have reported that
HbA1C does not improve prediction156 or reclassifica-
tion.160 However, other studies have observed that in
persons without diabetes, higher levels of HbA1C are
associated with an increased risk of CVD.161 In a 2010
report using data from the ARIC (Atherosclerosis Risk in
Communities) study, it was demonstrated that in persons
without diabetes, prediction models including HbA1C
levels were associated with improved risk prediction,
discrimination, and reclassification compared with predic-
tion models that included standard risk factors and fasting
glucose.155 This study is the strongest evidence available
concerning the potential value of HbA1C for CVD risk
assessment in asymptomatic persons without diabetes. As
with most other novel markers of CVD risk, it is unknown
whether HbA1C is useful for motivating individuals to
adhere to preventive interventions in the absence of
diagnosed diabetes.2.4.4. Urinary Albumin Excretion
2.4.4.1. Recommendations for Testing for Microalbuminuria
Class IIa
1. In asymptomatic adults with hypertension or diabetes,
urinalysis to detect microalbuminuria is reasonable for
cardiovascular risk assessment.162–164 (Level of Evi-
dence: B)
Class IIb
1. In asymptomatic adults at intermediate risk without
hypertension or diabetes, urinalysis to detect mi-
croalbuminuria might be reasonable for cardiovascu-
lar risk assessment.165 (Level of Evidence: B)
2.4.4.2. General Description
Urinalysis for microalbuminuria is widely available, inexpen-
sive, and associated with cardiovascular events.166 The ADA
recommends annual urinalysis for detection of microalbumin-
uria in persons with diabetes mellitus.167 A recent meta-
analysis showed that increased risk of CVD associated with
microalbuminuria was present in persons both with and
without diabetes.166 However, standardization of the mea-
surement of urine albumin across laboratories is subopti-
mal.168,169 It is logistically difficult for most patients to
perform 24-hour urine collection, but studies have demon-
strated that the first morning (“spot urine”) urinary albumin–
to-creatinine ratio has a similar ability to predict CVD
events.170 On the basis of the urinary albumin–to-creatinine
ratio on a morning spot urine sample, microalbuminuria is
defined as 30 to 300 mg/g and macroalbuminuria is defined as
300 mg/g.171 Blacks and Mexican Americans have a higher
prevalence of albuminuria than their Caucasian counterparts,
regardless of diabetes status.172 Longitudinal data from the
NHANES, between 1988–1994 and 1999–2004, found that
the prevalence of microalbuminuria had increased from about
7.1% to 8.2% (P0.01).173
Excretion of urinary albumin in the microalbuminuria
range is considered a candidate for CVD risk biomarker for
several reasons. Standard CVD risk factors are associated
with microalbuminuria.174,175 Microalbuminuria is associated
with incident hypertension, progression to a higher blood
pressure category, and incident diabetes.176,177 Microalbumin-
uria and diabetes each appear to influence the other’s pro-
gression.178 Furthermore, microalbuminuria has been associ-
ated with other novel risk factors for CVD, such as impaired
endothelial function and inflammatory markers such as
CRP.179–181 Microalbuminuria is considered to be an indica-
tor of vascular dysfunction and early CVD.182
2.4.4.3. Association With Cardiovascular Risk
A meta-analysis of 26 cohort studies with 169,949 participants
reported that after accounting for standard CVD risk factors,
there was a dose–response relationship between albuminuria and
risk of CHD.166 Compared with individuals without albumin-
uria, macroalbuminuria was associated with a doubling of risk
(RR 2.17; 95% CI 1.87 to 2.52), and microalbuminuria was
associated with a nearly 50% greater risk (RR 1.47; 95% CI 1.30
to 1.66) of CHD.166 The increased risk of CVD was present
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 across many different subgroups, including persons with and
without hypertension, with and without diabetes, and with and
without decreased estimated glomerular filtration rate.165,166,183
The prognostic importance of microalbuminuria also has been
observed in older and younger individuals and ethnic minorities,
including American Indians, South Asians, and African
Carribbeans.166,184–186
In studies examining the incremental yield of adding
urinary albumin excretion in the microalbuminuria range to
standard CVD risk factors for CVD risk prediction, the
Framingham Heart Study and the Cardiovascular Health
Study observed only minor improvements in the C statis-
tic.175,187 However, the Cardiovascular Health Study observed
that the urinary albumin–to-creatinine ratio did assist with
risk reclassification. Persons at intermediate risk (predicted
5-year Framingham risk of 5% to 10%) with a urinary
albumin–to-creatinine ratio 30 mg/g had a substantially
higher 5-year risk of CHD than those with a ratio of 30
mg/g (20.1% versus 6.3%, respectively).175
2.4.4.4. Usefulness in Motivating Patients or
Guiding Therapy
The writing committee is unaware of data that suggest that
knowledge of albuminuria improves patient motivation or
adherence to preventive therapies.
2.4.5. Lipoprotein-Associated Phospholipase A2
2.4.5.1. Recommendation for Lipoprotein-Associated
Phospholipase A2
Class IIb
1. Lipoprotein-associated phospholipase A2 (Lp-PLA2)
might be reasonable for cardiovascular risk assessment
in intermediate-risk asymptomatic adults.188–191 (Level
of Evidence: B)
2.4.5.2. General Description
Lp-PLA2, or platelet-activating factor acetylhydrolase, is a
proatherogenic enzyme produced by macrophages and
lymphocytes.192 Lp-PLA2 hydrolyzes oxidized phospho-
lipids in LDL, leading to the generation of lysophosphati-
dylcholine, oxidized nonesterified fatty acids, as well as
other active phospholipids and inflammatory mediators.192
Reported clinical correlates of increasing Lp-PLA2 mass
and activity include advanced age, male sex, smoking, and
LDL; Lp-PLA2 activity also was inversely associated with
HDL.193 There have been unexplained ethnic differences in
Lp-PLA2 concentrations; adjusting for standard CVD risk
factors, Lp-PLA2 activity was higher in white and His-
panic participants than in black participants.194
2.4.5.3. Association With Cardiovascular Risk
In a meta-analysis of 14 studies, Lp-PLA2 was associated
with an adjusted OR for CVD of 1.60 (95% CI 1.36 to
1.89).190 Although there was moderate heterogeneity
across studies in the meta-analysis, there was no significant
difference between Lp-PLA2 mass and activity for risk
prediction.190 A number of studies have reported that the
increased CVD risk of Lp-PLA2 remains after adjustingfor CRP, in addition to standard CVD risk factors.188,189,191
Several studies have examined whether Lp-PLA2 im-
proves risk discrimination over and above models account-
ing for standard risk factors. Both the ARIC study and
Rancho Bernardo study investigators observed that Lp-
PLA2 was associated with a statistically significant incre-
ment in the area under the curve (AUC) (P0.05),
although the increments were small (for the ARIC study,
0.774, increased to 0.780 with the addition of Lp-PLA2;
for the Rancho Bernardo study, change in ROC was 0.595
to 0.617).189,195 In a modest-sized study (n765), Lp-
PLA2 was associated with a nonsignificant 9.5% net
reclassification.196 These reports indicate that Lp-PLA2
has modest incremental risk prediction information, mean-
ing its use in intermediate-risk patients might be reason-
able. There is little information about the predictive
capability of Lp-PLA2 in ethnic minorities, because the
vast majority of studies reported to date have been con-
ducted in whites of European ancestry.190
2.4.5.4. Usefulness in Motivating Patients or
Guiding Therapy
Presently there is no information about whether Lp-PLA2
concentrations are clinically effective for motivating pa-
tients, guiding treatment, or improving outcomes. Ran-
domized studies have demonstrated that lipid-lowering
therapies reduce Lp-PLA2, although there may be some
variability by medication type.197,198 Drugs under develop-
ment that specifically inhibit Lp-PLA2 activity have been
shown to lower Lp-PLA2 activity and inflammatory
markers.199
2.5. Cardiac and Vascular Tests for Risk
Assessment in Asymptomatic Adults
2.5.1. Resting Electrocardiogram
2.5.1.1. Recommendations for Resting Electrocardiogram
Class IIa
1. A resting electrocardiogram (ECG) is reasonable for
cardiovascular risk assessment in asymptomatic adults
with hypertension or diabetes.200,201 (Level of Evidence: C)
Class IIb
1. A resting ECG may be considered for cardiovascular
risk assessment in asymptomatic adults without hyper-
tension or diabetes.202-204 (Level of Evidence: C)
2.5.1.2. General Description
Epidemiological studies have shown that abnormalities on a
resting 12-lead ECG are predictive of subsequent mortality
and cardiovascular events among asymptomatic
adults.200,202,205,206 Specific electrocardiographic findings that
have been linked to cardiovascular risk in population-based
cohorts and asymptomatic patients with hypertension include
LVH (especially when accompanied by repolarization
changes), QRS prolongation, ST-segment depression, T-wave
inversion, and pathological Q waves.202,207–211 Several studies
suggest that subtle electrocardiographic abnormalities detect-
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 able only by computer analysis may also be associated with
increased risk.212–214
The 12-lead resting ECG may provide information about
other CVD, particularly cardiac arrhythmias, by document-
ing extra systoles, atrial fibrillation, ventricular pre-
excitation, or prolonged QT interval. Many cardiomyopa-
thies display nonspecific electrocardiographic changes.
There has been interest in electrocardiographic abnormal-
ities that may be predictive of sudden cardiac death in
young, seemingly healthy athletes.215 The usefulness of
screening with ECGs for these disorders is beyond the
scope of the current document.
2.5.1.3. Association With Increased Risk and
Incremental Risk
Table 4 presents a sample of longitudinal studies that
report independent predictive value of different resting
electrocardiographic measures in asymptomatic popula-
tions. A number of classification schemes have been
Table 4. Sample of Longitudinal Studies Reporting the Independ
Asymptomatic Populations
Primary
Measurement(s)
First Author
(Year, Country) Type of Events
Fol
Novacode major
and minor
abnormalities
Denes (2007, US)216 Composite of
cardiovascular
events
Pooling project, major
and minor
abnormalities*
DeBacquer (1998,
Belgium)205
CHD and CVD
mortality,
all-cause
mortality
LVH with ST-
depression and
negative T wave
Larsen (2002,
Denmark)210
MI, incident
CHD, CVD
mortality
Unrecognized MI Sigurdsson (1995,
Iceland)211
Death from
CHD, stroke,
and all
causes
1
Minor ST-T
abnormalities
Daviglus (1999, US)207 All-cause, CHD,
and CVD
mortality
Digital ECG measures Gorodeski (2009, US)212 All-cause
mortality
*Major abnormalities include ST-segment depression, T-wave inversion, co
block, frequent premature beats, and atrial fibrillation or flutter. Minor abnorma
borderline ST-segment depression, T-wave flattening, and QRS low voltage.
CHD indicates coronary heart disease; CVD, cardiovascular disease; ECG
discrimination improvement; LVH, left ventricular hypertrophy; MI, myocardialdescribed that may be useful for risk stratification. Anexample is the Novacode criteria, which divide electrocar-
diographic abnormalities into major and minor types.216
Major abnormalities include atrial fibrillation or atrial
flutter, high-grade atrioventricular (AV) block, AV disso-
ciation, complete bundle-branch block, pathological T
waves, isolated ischemic abnormalities, LVH with accom-
panying repolarization abnormalities, and arrhythmias
such as supraventricular tachycardia and ventricular tachy-
cardia. Minor abnormalities include first- and second-
degree AV block, borderline prolongation of the QRS
interval, prolonged repolarization, isolated minor Q-wave
and ST-T abnormalities, LVH by voltage only, left atrial
enlargement, frequent atrial or ventricular premature beats,
or fascicular blocks. Electrocardiographic findings have
also been combined with echocardiography to improve risk
stratification in patients with hypertension.201
Abnormal Q waves on the ECG may indicate clinically
unrecognized or “silent” MI. In the Framingham Study, as
dictive Value of Resting ECG Measures in
Population
Characteristics
(No.)
Mean Age (y)
at Entry Main Findings: Adjusted HR
Women in the
Women’s
Health Initiative
trial (14,749)
64 For minor abnormalities, HR 1.6;
for major abnormalities HR 3.0;
C index increased by 0.05
compared with FRS
Population-based
sample (5,208
men, 4,746
women)
49 (men),
48 (women)
Major ECG abnormalities predicted
all-cause mortality (HR 1.8), CV
mortality (HR 3.3), and CHD
mortality (HR 2.3). Minor ECG
abnormalities were not
predictive.
Population-based
sample (5,243
men, 6,391
women)
53 Predictive of MI (HR 1.9), incident
CHD (HR 2.2), and cardiovascul
mortality (HR 1.9)
Icelandic Heart
Association
Preventive
Clinic, all men
(9,141)
52-58 Predictive of CHD death (HR 4.6)
and all-cause death (HR 2.7)
Men employed at
an electric
company
(1,673)
48 Predictive of death due to CHD
(HR 1.7), CVD (HR 1.4), and all
causes (HR 1.3)
Ambulatory
patients
without known
CVD (18,964)
51 Combined ECG measures predictiv
of all-cause death (HR 1.4,
comparing 75th to 25th
percentiles; C index increased b
0.04 compared with standard
predictors; relative IDI increased
by 3%)
or second-degree atrioventricular block, complete left or right bundle-branch
lude nonpathological Q wave, a left- or right-axis deviation, QRS high voltage,
cardiogram; FRS, Framingham risk score; HR, hazard ratio; IDI, integrated
n; and US, United States.ent Pre
low-Up
(y)
3
10
21
0
29
11
mplete
lities inc
, electromany as one quarter of nonfatal MIs were found only through
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 ECG changes.217 In a number of population studies, Q waves
on the ECG indicate a higher cardiovascular risk.202,211
Electrocardiographic LVH and associated repolarization
abnormalities have been predictive of subsequent cardio-
vascular risk in numerous prospective epidemiological
studies, including the Framingham Study. LVH on a
resting ECG may indicate more severe or poorly controlled
hypertension, which in turn increases cardiovascular
risk.218 In 1 large randomized trial that specifically focused
on patients with electrocardiographic LVH, regression of
left ventricular mass as assessed by ECGs was a predictor
of a lower risk of major cardiovascular events.219
Few studies have evaluated the ability of the resting
ECG to improve discrimination and reclassify risk com-
pared with standard risk assessment. In 14 749 asymptom-
atic, postmenopausal women enrolled in the Women’s
Health Initiative, the resting ECG increased the C statistic
over the FRS from 0.69 to 0.74 for prediction of CHD
events.216 In 18 964 Cleveland Clinic patients without
known CVD, the resting ECG similarly increased the C
statistic by 0.04 and modestly improved reclassification
(relative integrated discrimination improvement, 3%,
P0.001).212
2.5.1.4. Usefulness in Motivating Patients, Guiding Therapy,
and Improving Outcomes
There have been no randomized trials demonstrating that
findings on a resting ECG can be used to motivate better
lifestyle behaviors in the asymptomatic adult. One large
randomized trial offered suggestive evidence that electro-
cardiographic assessment of left ventricular mass may be
useful for guiding antihypertensive therapy, because re-
gression of electrocardiographic LVH was associated with
reduced risk for sudden death,220 atrial fibrillation,219 heart
failure,221 major CVD events,200 and diabetes.222 However,
no randomized trial has directly addressed this question.223
One policy-based intervention study found that an ECG-
based screening program for competitive athletes may
have reduced the population risk of sudden cardiac death
among young adults.224
2.5.2. Resting Echocardiography for Left Ventricular
Structure and Function and Left Ventricular Hypertrophy:
Transthoracic Echocardiography
2.5.2.1. Recommendations for
Transthoracic Echocardiography
Class IIb
1. Echocardiography to detect LVH may be considered
for cardiovascular risk assessment in asymptomatic
adults with hypertension.225,226 (Level of Evidence: B)
Class III: No Benefit
1. Echocardiography is not recommended for cardiovas-
cular risk assessment of CHD in asymptomatic adults
without hypertension. (Level of Evidence: C)
2.5.2.2. Left Ventricular Function
Transthoracic echocardiography is a diagnostic modality
widely used in cardiology practice. There are no echocardio-graphic findings with high sensitivity and specificity for the
diagnosis of CHD in the absence of ischemia or infarction.
Segmental wall motion abnormalities are the most common
echocardiographic manifestation of CHD but are only present
if there is active or recent (stunning) ischemia or there has
been prior infarction. Moreover, segmental wall motion
abnormalities do not uniformly represent ischemic territories
caused by occlusive CAD, because they may also be present
in patients with nonischemic cardiomyopathies. Additional
manifestations of CHD include ischemic mitral regurgitation,
global reduction in left ventricular systolic function, Doppler
findings characteristic of diastolic dysfunction, and right
ventricular dysfunction. However, none of these findings has
sufficient sensitivity or specificity to be useful for screening
or risk assessment in the asymptomatic patient at possible risk
for CHD. Given the lack of evidence of risk assessment
benefit in the general population, it was the consensus of the
writing committee that echocardiography should not be per-
formed for risk assessment in the asymptomatic adult without
hypertension.
2.5.2.3. Left Ventricular Hypertrophy
LVH develops in response to varying stimuli and may be
physiological in the setting of athletic training and pregnancy
or pathological in response to pressure or volume overload,
myocardial injury, or underlying genetic mutations. The
pathophysiological mechanism for higher cardiovascular
mortality in the setting of LVH is not completely understood,
although studies have demonstrated decreased flow reserve
and greater susceptibility to injury associated with ischemia
and infarction.227 The methodology for LVH measurement by
echocardiography and the cut points for definition of LVH
vary widely among studies. There is also wide variability as
to whether LVH is indexed to body surface area, height, or
weight.227,228 A recent meta-analysis of 34 studies showed
that 19 different criteria were used, leading to differences in
the prevalence of LVH.229 The writing committee recom-
mends the use of the methodology and cut points defined by
the ASE.230 Separate cut points should be applied to men and
women. Further studies may suggest that the definition of
pathological LVH should be specific to race as well as sex. A
recent study showed that athletic hypertrophy in African/
Afro-Caribbeans (blacks) was greater than in whites.231
LVH has been shown to be predictive of cardiovascular
(including stroke) and all-cause mortality, independent of
blood pressure, and across all racial groups that have been
studied. In the predominantly white population of the
Framingham Study, for every 50 g/m2 higher left ventric-
ular mass index, there was a RR of death of 1.73 (95% CI
1.19 to 2.52) independent of blood pressure level.232 In the
African-American population enrolled in the ARIC study,
LVH conferred an increased risk for CVD events (nonfatal
MI, cardiac death, coronary revascularization, and stroke)
even after adjusting for other risk factors with a HR of 1.88
in men and 1.92 in women.228 Among American Indians
enrolled in the Strong Heart Study (64% female, mean age
equal to 58), the prevalence of LVH on echocardiography
was 9.5% and conferred a 7-fold increase in cardiovascular
mortality and a 4-fold increase in all-cause mortality.201 In
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 this study, echocardiographic evidence of LVH had addi-
tive discriminatory power over ECG evidence of LVH.
Data from a Hispanic population226 are similarly sugges-
tive of the association of LVH and cardiovascular mortal-
ity. The association of LVH and mortality in many of these
studies cannot be attributed only to the risk of developing
atherosclerotic CHD, because patients with hypertrophic
cardiomyopathy who die suddenly may be misclassified.
Recent estimates suggest a 1 in 500 prevalence of hyper-
trophic cardiomyopathy in the population, which may
contribute to the association between LVH and cardiovas-
cular (including stroke) and all-cause mortality.
LVH is considered evidence of target organ damage in
hypertension according to JNC 7.233 The epidemiological
association between pathological hypertrophy and CVD
has also been studied in hypertensive populations.201,226
For example, in the MAVI (Massa Ventricolare sinistra
nell’Ipertensione) study of patients with uncomplicated
essential hypertension, there was a 40% higher risk of
cardiovascular events for each 39 g/m2 greater left ven-
tricular mass index.225 Left ventricular architecture is also
an important variable related to risk, with most studies
suggesting that the presence of concentric rather than
eccentric hypertrophy in the hypertensive population car-
ries the highest risk.
2.5.2.4. Usefulness in Motivating Patients or
Guiding Therapy
Although the finding of increased left ventricular mass on
echocardiography could be envisioned to guide selection or
intensity of therapy in hypertensive patients, JNC 7 recom-
mendations do not risk stratify patients on the basis of target
organ damage.233 Given the adverse prognosis associated
with LVH in hypertension, further studies examined the
comparative efficacy of specific antihypertensive agents in
regressing LVH as well as survival benefits associated with
LVH regression, but there was a lack of consistency among
the trials. In a meta-analysis of 39 trials of antihypertensive
therapy, angiotensin-converting enzyme inhibitors were the
most effective agents, leading to a 13.3% reduction in left
ventricular mass compared with 9.3% for calcium channel
blockers, 6.8% for diuretics, and 5.5% for beta blockers.234 In
a comparison of enalapril and long-acting nifedipine in
patients with essential hypertension, the PRESERVE (Prospec-
tive Randomized Enalapril Study Evaluating Regression of
Ventricular Enlargement) trial, a prospective randomized
enalapril study evaluating regression of ventricular enlarge-
ment, systolic and diastolic pressures as well as left ventric-
ular mass were reduced to a similar degree with both
agents.235 The LIFE (Losartan Intervention For Endpoint
Reduction in Hypertension) trial echocardiographic substudy
demonstrated superior left ventricular mass reduction (21.7
g/m2) in patients treated with losartan compared with patients
treated with atenolol (17.7 g/m2).218 Diuretics demonstrated
superiority in treating LVH regression over alternative agents
in both the TOMHS (Treatment of Mild Hypertension Study)
and Department of Veterans Affairs Cooperative Study Group
on Antihypertensive Agents, using chlorthalidone and hydro-
chlorthiazide, respectively.236,237LVH regression does not adversely affect cardiac function
and may be associated with improvements in diastolic func-
tion. Most importantly, patients who demonstrate LVH re-
gression on antihypertensive therapy have a lower rate of
cardiovascular events than those who do not, independent of
the extent of blood pressure control.238,239
Despite these observations, there have been no trials that
target antihypertensive therapy to regress echocardiographi-
cally detected LVH, and thus the results continue to generate
hypotheses.
No studies have examined whether a patient’s knowledge
of echocardiographic results demonstrating LVH will im-
prove adherence to lifestyle modifications or pharmacologic
treatment of hypertension.
2.5.3. Carotid Intima-Media Thickness on Ultrasound
2.5.3.1. Recommendation for Measurement of Carotid
Intima-Media Thickness
Class IIa
1. Measurement of carotid artery IMT is reasonable for
cardiovascular risk assessment in asymptomatic adults
at intermediate risk.240,241 Published recommendations
on required equipment, technical approach, and oper-
ator training and experience for performance of the
test must be carefully followed to achieve high-quality
results.241 (Level of Evidence: B)
2.5.3.2. General Description
Carotid IMT testing is a noninvasive, nonionizing radiation
test using ultrasound imaging of the carotid artery wall to
define the combined thickness of the intimal and medial
arterial wall components. It is most commonly measured in
the far wall of the common carotid artery; however, it can
also be measured in the near wall and other carotid segments
(bulb, internal). With well-trained operators, the test has been
shown to be highly accurate with excellent intertest and
interobserver reproducibility primarily in research settings
and less commonly in practitioner-based settings.242 The
available data on risk associated with carotid IMT are drawn
almost exclusively from research settings using highly stan-
dardized protocols. The use of common carotid IMT as a
standard site of measurement has been proposed due to its
inherent greater reproducibility and ability to refine the
cardiovascular risk prediction. Published recommendations
on the required equipment, technical approach, and operator
training and experience for performance of the test must be
carefully followed to achieve high-quality results.241,243 There
is a need for provider competency and lab accreditation
standards to ensure quality imaging. An elevated level of
carotid IMT is commonly cited as a level that surpasses the
population-based 75th percentile value, but this must be
identified specific to a particular carotid arterial segment (eg,
common or internal carotid artery) and ultrasound methodol-
ogy for which tables are available.241
2.5.3.3. Independent Relationship Beyond Standard
Risk Factors
Carotid IMT has been independently associated with future
risk for ischemic coronary events and stroke in middle-aged
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 and older individuals.244 The risk of incident CHD events
increases in a continuous fashion as carotid IMT increases
(RR increases approximately 15% per 0.10-mm increase in
carotid IMT); thus, measurement of carotid IMT has been
shown in research studies to be a marker of risk for athero-
sclerotic CVD. Furthermore, the finding of atherosclerotic
plaque, operationally defined as a focal increase in thickness
50% of the surrounding IMT, increases the predicted CAD
risk at any level of carotid IMT.245 These values were
determined after adjustment for traditional CVD risk factors.
The relationship between carotid IMT and incident CHD
events was initially noted in the Kuopio Ischemic Heart
Disease Risk Factor study, in which risk of future MI in
Finnish men increased by 11% for every 0.1-mm increment in
carotid IMT.246 For carotid IMT values 1 mm, there was a
2-fold greater risk of acute MI over 3 years. The ARIC study
showed that for every 0.19-mm increment in carotid IMT,
risk of death or MI increased by 36% in middle-aged patients
(45 to 65 years of age).247 CHD risk was almost 2-fold greater
in men with mean carotid IMT 1 mm and even greater in
women (RR 5.0). Not all studies, however, have shown
differences between men and women in the predictive value
of carotid IMT. For example, the Rotterdam study found that
the risk of CHD events and carotid IMT was similar among
men and women.248
The association between carotid IMT and incidence of MI
and stroke has been noted in older populations and other
high-risk populations. In the Cardiovascular Health Study,
the RR for MI, adjusted for age, gender, and standard
cardiovascular risk factors, was 3.15 (95% CI 2.19 to 4.52)
when an average IMT was used for the common carotid and
internal carotid arteries and when comparing the highest
quintile versus the lowest quintile. These differences held true
for patients with and without known CVD.249 Among middle-
aged adults with diabetes mellitus in the ARIC study, an IMT
1 mm was associated with an increase in the ROC AUC
from 0.711 to 0.724 among women and 0.680 to 0.698 in
men250 when this elevated IMT was included in traditional
risk factor predictive models. Similarly, in the Cardiovascular
Health Study, the incidence of CAD was shown to increase
from 2.5% to 5.5% per year among patients with diabetes
with subclinical vascular disease.251
Carotid IMT measurement can lead to improved cardio-
vascular risk prediction and reclassification. In the ARIC
study, 13 145 individuals were followed for approximately
15 years for incident hard coronary events and revasculariza-
tion. Carotid IMT measurements, which included both IMT
and carotid plaque, were incremental to traditional risk
factors for prediction of incident cardiovascular events. In
particular, among intermediate-risk patients (10% to 20%,
10-year estimated risk group), the addition of carotid IMT
and plaque information led to clinical net reclassification
improvement of approximately 9.9%.240
Comparisons of carotid IMT with coronary calcium scor-
ing as methods to modify cardiovascular risk assessment have
been made in both middle-aged (MESA) and older individ-
uals (Cardiovascular Health Study). Each study showed that
carotid IMT was an independent predictor of cardiovascular
outcomes. Coronary calcium was a relatively stronger predic-tor for coronary outcomes, whereas carotid IMT was a
stronger predictor of stroke in MESA.252 In contrast, signif-
icant and similar magnitude relationships to cardiovascular
outcomes (HRs for fourth quartile versus first quartile for
each test, approximately 2.1) were observed in the Cardio-
vascular Health Study for both tests.253 Given the discrepancy
between these available studies, the data are insufficient to
conclude whether these tests are clinically equivalent or not.
Thus, at this time, test selection in clinical practice is better
guided by local and patient factors such as expertise, cost, and
patient preference.
Epidemiological studies demonstrate that IMT typically
progresses at an average rate of 0.03 mm per year, and the
rate of progression appears to be related to risk of cardiovas-
cular event.254 Progression can be slowed by cholesterol-
lowering drugs (statins and niacin) and other risk factor
modifications (eg, control of blood pressure). However, serial
scanning of carotid IMT is challenging in individual patients
across brief time horizons due to variability in measurement
in relation to the rate of disease progression and is therefore
not recommended in clinical settings.
Images of subclinical atherosclerosis are hypothesized to
alter patient behavior, but the evidence is insufficient.255
2.5.3.4. Usefulness in Motivating Patients or
Guiding Therapy
The finding of increased carotid IMT should clinically guide
selection or intensity of therapy. However, evidence is
lacking regarding whether measurement of carotid IMT alters
outcome (Table 5). Clinical tools integrating carotid IMT
within global risk scoring systems are not available.
2.5.3.5. Evidence for Improved Net Health Outcomes
The incremental value of carotid IMT and cost-effectiveness
beyond that available from standard risk assessments to
improve overall patient outcomes is not established.
2.5.4. Brachial/Peripheral Flow-Mediated Dilation
2.5.4.1. Recommendation for Brachial/Peripheral
Flow-Mediated Dilation
Class III: No Benefit
1. Peripheral arterial flow-mediated dilation (FMD) stud-
ies are not recommended for cardiovascular risk as-
sessment in asymptomatic adults.256,257 (Level of Evi-
dence: B)
2.5.4.2. General Description
Peripheral arterial FMD is a noninvasive measure of endo-
thelial function. Augmented flow is produced by a sustained
period (typically 4 to 5 min) of forearm compression accom-
panied by vascular occlusion followed by release. In the
setting of healthy endothelium, increased flow stimulates
release of nitric oxide, inducing local brachial artery vasodi-
lation. The degree of dilation can be measured using high-
resolution ultrasound. The technique requires a highly skilled
sonographer, highly standardized measurement conditions
(including time of day, temperature, drug administration), and
suitable ultrasound machine. Many examiners also use spe-
cialized computer software to semiautomatically quantitate
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 the brachial artery diameter. Considerable variability exists
for values of FMD determined by different investigators, even
in similar patient populations, suggesting technical challenges
with the measurement.258 Important technical factors influ-
encing FMD are duration of forearm occlusion and the
location of the occluding cuff, but many other factors are also
important, as mentioned above. In research settings, brachial
artery FMD has been shown to correlate with invasive
measures of coronary artery FMD after adenosine triphos-
phate infusion, suggesting that peripheral FMD may be a
suitable substitute for invasive coronary endothelial function
testing.257 FMD also correlates with other noninvasive mea-
sures of cardiovascular risk, including CRP, carotid IMT, and
measures of arterial stiffness.
PAT is a second method of assessing postocclusion
vasodilation. This method uses bilateral finger cuffs that
sense pulse wave volume. After a 5-minute flow occlusion
in 1 arm, the resulting augmentation of pulse volume in the
occlusion arm is compared with the control arm, yielding
a PAT ratio. The PAT ratio provides information similar to
FMD.256,259
2.5.4.3. Association With Increased Risk and
Incremental Prediction
Many studies have documented a relationship between FMD,
PAT, and traditional CVD risk factors. FMD and PAT ratios
are lower (abnormal) in subjects with greater numbers of risk
factors or higher levels of FRS. Diabetes and smoking have
the most powerful associations with abnormal FMD. A
meta-regression analysis of 211 publications reported on 399
populations where both FMD and traditional risk factors were
available.260 By design, many of these populations had
existing CVD. The relationship between FMD and risk
Table 5. Summary of Prospective Studies Evaluating Carotid IMT
Pat
Study,
Participants
Carotid IMT
Measurement Clinical Events
KIHD, 905112 CCA/carotid bifurcation* Fatal/nonfatal MI 1
ARIC, 12 841247 CCA/ICA/carotid
bifurcation†
Fatal/nonfatal MI
CHS, 4476249 CCA/ICA‡ MI/stroke
Rotterdam Study,
7983248
CCA¶ MI/stroke
MESA, 6698252 CCA Cardiovascular
events
*Mean carotid IMT.
†Mean far wall, internal carotids, and bifurcation.
‡Mean of CCA and ICA.
§OR is risk for MI and coronary death only; OR for MI and stroke was 1.4
CCA, carotid IMT.
¶Mean CCA.
#OR is for risk of MI only.
ARIC indicates Atherosclerosis Risk in Communities study; CCA, common
confidence interval; ICA, internal carotid artery; IMT, intima-media thickness; KI
MI, myocardial infarction; and OR, odds ratio.factors was most clear in the category with the lowestbaseline risk. In this group, for each percentage point higher
FRS, FMD was lower by 1.42%. In populations with an
intermediate or high FRS, FMD was not related to the score.
This finding fits with the hypothesis that FMD is an early
marker of vascular dysfunction. Once multiple risk factors are
present, FMD may become so impaired that additional risk
factors do not further impair it.
PAT ratio was measured in the Framingham Third Gener-
ation Cohort (n1957).261 In a stepwise multivariable regres-
sion model, PAT ratio was inversely related to male sex, body
mass index, total/HDL-cholesterol ratio, diabetes, smoking,
and lipid-lowering treatment. In this study, hypertension was
not related to PAT.
It is unclear whether these measures of peripheral endo-
thelial health provide incremental predictive information
when controlling for traditional risk factors. The relationship
between FMD and incident cardiovascular events was re-
ported in a population-based cohort of older adults.262 In the
Cardiovascular Health Study, 2792 (2791 with complete data)
adults aged 72 to 98 years underwent FMD measures.262
During 5-year follow-up, 24.1% of these subjects had events.
At study entry, 76% of this population (n2125) was free of
known CVD. In the subset without known CVD at entry, the
predictive value of FMD (after adjustment for age, gender,
diabetes, blood pressure, cholesterol, and HMG-CoA
[3-hydroxy-3-methylglutaryl-coenzyme A] reductase inhibi-
tor use) was directionally similar to the whole population but
failed to achieve statistical significance (P0.08). The addi-
tion of brachial FMD to the predictive model containing the
classical cardiovascular risk factors increased the AUC by a
net change of only 0.001, and the P value for the increase was
not significant (area under receiver operating statistic 0.841
ncident Coronary Events in Patients Without Known CHD
ils
p
Age (y) Sex
Carotid IMT
Increment
(mm) OR (95% CI)
y 42 to 60 Men 0.1 1.11 (1.06 to 1.16)
45 to 64 Men
Women
0.19
0.19
1.36 (1.23 to 1.51)
1.69 (1.50 to 1.90)
65 Men and
women
0.20 1.46 (1.33 to 1.60)§
55 Men
Women
0.163
0.163
1.56 (1.12 to 2.18)#
1.44 (1.00 to 2.08)#
45 to 64 Men and
women
0.19 1.30 (1.10 to 1.40)
CI 1.37 to 1.67).
artery; CHD, coronary heart disease; CHS, Cardiovascular Health Study; CI,
pio Ischemic Heart Disease study; MESA, Multi-Ethnic Study of Atherosclerosis;and I
ient Deta
Follow-U
(y)
mo to 3
2 to 7
6.2
2.7
3.9
7 (95%
carotid
HD, Kuoversus 0.842). NOMAS (Northern Manhattan Study), a
e606 Circulation December 21/28, 2010
 by guest on A
pril 2, 2018
http://circ.ahajournals.org/
D
ow
nloaded from
 smaller multiethnic, prospective cohort study of 842 subjects
free of CVD examined the relationship of FMD to 36-month
cardiovascular events.263 Although FMD was associated with
the occurrence of future events (HR 1.12 for every 1%
decrease in FMD), the association was no longer statistically
significant when traditional cardiovascular risk factors were
included in a multivariable analysis. In contrast, a study of
2264 asymptomatic postmenopausal women found that FMD
was independently related to cardiovascular events (RR 1.12;
95% CI 1.04 to 2.00; P0.001) when included in a model
with traditional risk factors.264 No measures of reclassifica-
tion were reported in this study.
2.5.4.4. Usefulness in Motivating Patients or
Guiding Therapy
There is no evidence that arterial FMD studies are useful for
motivating asymptomatic persons to adhere to preventive
therapies.
In a study of 400 hypertensive postmenopausal women
followed up for an average of 67 months,265 endothelial
function was measured as FMD of the brachial artery at
baseline and at 6 months after initiation of blood pressure
control. After 6 months of treatment, FMD had not changed
(10% relative to baseline) in 150 (37.5%) of the 400
women, whereas it had significantly improved (10% rela-
tive to baseline) in the remaining 250 women (62.5%).
During follow-up, failure to have an improved FMD at 6
months was an independent predictor of nonfatal cardiovas-
cular events requiring hospitalization. This study demon-
strates that a significant improvement in endothelial function
may be obtained after 6 months of antihypertensive therapy
and also appears to identify patients who may have a more
favorable prognosis.
Due to the limited data available, the writing committee
concluded that it was premature to recommend serial FMD
measurements to monitor treatment effects. In addition, due to
the technical challenges of standardizing measurement of
FMD and the relatively modest evidence of incremental
change in risk assessment, measurement for risk assessment
was not regarded as appropriate for risk assessment in the
asymptomatic adult.
2.5.4.5. Changes in Patient Outcomes
To date, there are no published trials evaluating the impact of
specific therapy on clinical outcome in patients identified as
having abnormal peripheral endothelial function.
2.5.5. Pulse Wave Velocity and Other Arterial Abnormali-
ties: Measures of Arterial Stiffness
2.5.5.1. Recommendation for Specific Measures of
Arterial Stiffness
Class III: No Benefit
1. Measures of arterial stiffness outside of research settings
are not recommended for cardiovascular risk assessment
in asymptomatic adults. (Level of Evidence: C)
2.5.5.2. Description of Specific Measures of Arterial Stiffness
Arterial stiffness is a consequence of arteriosclerosis, the
process of arterial wall thickening, and loss of elasticity thatoccurs with onset of vascular disease and advancing age.
Besides pulse pressure (the numeric difference between the
systolic and diastolic blood pressures), multiple other specific
measures of arterial stiffness have been described.98,266,267
The most commonly studied measures of arterial stiffness are
aortic pulse wave velocity (PWV) and pulse wave analyses
such as the aortic augmentation index.266
Because blood is a noncompressible fluid, transmission of
the arterial pressure wave occurs along the arterial wall and is
influenced by the biomechanical properties of the arterial
wall. When the arteries are stiffened, the pulse wave is
propagated at an increased velocity, and increased PWV is
therefore correlated with stiffness of the arteries. Factors
associated with PWV include advancing age as well as the
long-term effects of cardiovascular risk factors on the struc-
ture and function of the arterial wall. PWV is generally
measured using applanation tonometry but can also be mea-
sured by Doppler ultrasound or magnetic resonance imaging
(MRI). MRI is more costly and therefore is typically not used
for testing in asymptomatic persons.
Pulse wave analysis is based on the concept that the
pressure wave is partially reflected back toward the aorta at
various points of discontinuity in arterial elasticity. Appla-
nation tonometry is considered a relatively simple and
reproducible method of collecting data for pulse wave
analysis in research settings. The most commonly reported
measure in pulse wave analysis is expressed as a fraction
of the central pulse pressure, called the aortic augmenta-
tion index. The augmentation index is said to be most
useful in patients under the age of 60 years.266 Both pulse
wave analysis and PWV are typically determined by
commercial devices that perform the analyses based on
proprietary analytic algorithms.267
Although predictive information (see below and Table 6)
suggests a potential clinical role for measures of arterial stiffness,
there are a number of technical problems that the writing
committee believed would restrict the applicability of measures
of arterial stiffness predominantly to research settings at this
time.266,267 For measures of arterial stiffness to be incorporated
into clinical practice, measurement protocols must be well
standardized, quality control procedures established, and risk-
defining thresholds identified.266 Reproducibility is a problem, as
is operator dependence, both of which limit the generalizability
of findings derived from research studies. Additional technical
concerns include the need to standardize room temperature, time
of day of testing, keeping the patient at rest for at least 10
minutes before measurements are recorded, and careful attention
to timing of drug and caffeine intake.267 The writing committee
felt that the technical concerns make arterial stiffness tests less
suitable for addition to the clinical practice of risk assessment in
asymptomatic adults due to problems with measurement and
data collection.
2.5.5.3. Evidence on the Association With Increased
Cardiovascular Risk and Incremental Risk
From the standpoint of predictive studies within general
“healthy” populations, measures that have been studied are
the PWV, ambulatory arterial stiffness index, and carotid
pulse pressure (versus brachial pulse pressure). Predictive
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results in general populations are summarized for 11
longitudinal studies in Table 6. Although a few of these
studies have reported no predictive capability of these
measures of arterial stiffness, most studies indicated pre-
dictive capability that is additive to standard risk factors,
including (in some cases) systolic and diastolic blood
pressures as well as ankle-brachial index (ABI). In some
studies, but not all, HRs have been higher for stroke risk
than for CAD risk. No studies have directly compared
these measures of CVD risk with other measures of
“subclinical” CVD such as arterial IMT or CAC score.
HRs have generally been in the very modest predictive
range of 1.1 to 1.3 for various measures of arterial stiffness
and CHD outcomes. Information on changes in the C
statistic or other measures of incremental risk stratification
Table 6. Longitudinal Studies Reporting the Independent Predict
Primary
Measurement Type
First Author
(Year, Country) Type of Events
Follow-Up
(y)
Aortic PWV Meaume (2001,
France)268
CV mortality 2.5
D (strain) as
primary measure
Stork (2004,
the Netherlands)269
CV and all-
cause
mortality
4.0
Aortic PWV Sutton-Tyrrell (2005,
US)270
CV mortality and
events
4.6
Aortic PWV Shokawa (2005,
Japan)271
CVD mortality 10
Ambulatory arterial
stiffness index
Dolan (2006,
Ireland)272
CVD mortality 5.3
Aortic PWV Willum-Hansen
(2006,
Denmark)273
Fatal and
nonfatal CVD
and CHD
9.4
Ambulatory arterial
stiffness index
Hansen (2006,
Denmark)274
Fatal and
nonfatal CVD
and stroke
9.4
Carotid-femoral
PWV index
Mattace-Raso
(2006,
the Netherlands)275
CVD, CHD,
stroke,
all-cause
4.1
CPP versus BPP Roman (2007,
US)276
CVD, fatal and
nonfatal
4.8
CD, CPP, BPP Leone (2008,
France)277
CHD, fatal and
nonfatal
4
CPP and BPP Pini (2008, Italy)278 Total CV events
(fatal and
nonfatal)
8
BPP indicates brachial pulse pressure; CD, carotid distension; CHD, coronary
CVD, cardiovascular disease; HR, hazard ratio; NS, nonsignificant; PP, pulse pre
T, tertile; and US, United States.has generally not been reported.2.5.5.4. Usefulness in Motivating Patients or
Guiding Therapy
No information has been reported on any of these topics in
well-conducted studies of populations of healthy adults.
2.5.6. Recommendation for Measurement of
Ankle-Brachial Index
Class IIa
1. Measurement of ABI is reasonable for cardiovascular
risk assessment in asymptomatic adults at intermediate
risk.279 (Level of Evidence: B)
2.5.6.1. General Description
The ABI is an office-based test to check for the presence of
PAD. It is performed by Doppler measurement of blood
ue of Arterial Stiffness in Asymptomatic Populations
tion Characteristics (No.)
Mean Age (y)
at Entry Main Findings: Adjusted HR
men and women
70 y) (141)
87 1.19 (95% CI 1.03 to 1.37)
for total CVD mortality
(top decile)
men367 78 No stiffness measure
associated with outcomes
, both sexes 2,488 in
th ABC study
55 RR 1.15 to 1.30; P0.019
for Q4:Q1 for CHD; RR
2.6; P0.004 for stroke
Q4:Q1
l population, both sexes
)
63.7 Top 40%: 4.2 (95% CI 1.39
to 12.96; P0.01)
l population, both sexes,
16 to 96 y 11,291
54.6 1.16 (95% CI 1.05 to 1.27) in
fully adjusted model for
total CVD death
l population (1678), both
s, ages 40 to 70 y
51 HR 1.15 (95% CI 1.01 to
1.30) per 1 SD increase for
all endpoints
l population (1678), both
s, ages 40 to 70 y
51 HR 1.6 (95% CI 1.14 to
2.28; P0.007) for stroke,
but NS for CHD and
CVD
y elderly, both sexes
5); Rotterdam study
71.7 1.9 to 2.0 for T3:1 for CVD,
CHD, stroke
y American Indians, both
s,2,403 Strong Heart Study
63 Aortic PP, 1.12 per
10 mm Hg, P0.008
unity elderly (age
y),3,337 Three-City study
73.2 CD, 2.0 (95% CI 1.27 to
3.17) for T3:T1; CPP, 2.1
(95% CI 1.24 to 3.70) for
T3:T1; BPP, 2.1 (95% CI
1.38 to 3.40) for
T3:T1
unity elderly
65 y)173
73 BPP, NS; CPP HR 1.23 (95%
CI 1.11 to 1.38; P0.001)
per 10 mm Hg
sease; CI, confidence interval; CPP, carotid pulse pressure; CV, cardiovascular;
WV, pulse wave velocity; Q, quartile; RR, relative risk; SD, standard deviation;ive Val
Popula
Elderly
(age
Elderly
Elderly
Heal
Genera
(492
Genera
ages
Genera
sexe
Genera
sexe
Health
(283
Health
sexe
Comm
65
Comm
(age
heart di
ssure; Ppressure in all 4 extremities at the brachial, posterior tibial,
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 and dorsalis pedis arteries. The highest lower-extremity blood
pressure is divided by the highest of the upper-extremity
blood pressures, with a value of 0.9 indicating the presence
of PAD, which is defined as50% stenosis. When defined in
this way, the ABI has both a high sensitivity and specificity
for anatomic stenosis. In addition to signifying PAD, an
abnormally low ABI has also been shown to be a predictor of
cardiovascular events. Intermediate values (0.9 to 1.1) also
have a graded association with CVD risk. A high ABI (1.3),
which indicates calcified, noncompressible arteries, is also a
marker of arterial disease. The prevalence of PAD as indi-
cated by an abnormal ABI increases with age and is associ-
ated with traditional risk factors for CVD.280,281
2.5.6.2. Association With Increased Risk
Many epidemiological studies have demonstrated that an abnor-
mal ABI in otherwise asymptomatic individuals is associated
with cardiovascular events.279,282–293 A recent collaborative
study combined data from 16 studies279 and included a total of
24 955 men and 23 399 women without a history of CHD.
Importantly the study included data from a wide representation
of the population, including blacks, American Indians, persons
of Asian descent, and Hispanics as well as whites.288,293–295 The
mean age in the studies ranged from 47 to 78 years, and the
FRS-predicted rate of CHD ranged from 11% to 32% in men
and from 7% to 15% in women. There were 9924 deaths (25%
due to CHD or stroke) over 480 325 patient-years of follow-up.
For an ABI of 0.9 compared with an ABI of 1.11 to 1.4, the
HR for cardiovascular mortality and major events was 3.33 for
men and 2.71 for women.279 When adjusted for the FRS, the
HRs were only moderately lower (2.34 in men and 2.35 in
women), demonstrating the additive predictive value of the ABI
beyond the FRS.279 An ABI of 1.4 was also associated with
higher risk within most of the FRS categories. However, the
greatest incremental benefit of ABI for predicting risk in men
was in those with a high FRS (20%), in whom a normal ABI
reduced risk to intermediate.279 In women the greatest benefit
was in those with a low FRS (10%), in whom an abnormally
low or high ABI would reclassify them as high risk, and in those
with an intermediate FRS, who would be reclassified as high risk
with a low ABI. Reclassification occurred in 19% of men and
36% of women. Thus, an abnormally low or abnormally high
ABI is associated with increased cardiovascular risk in both men
and women, and the risk prediction extends beyond that of the
FRS alone.
2.5.6.3. Usefulness in Motivating Patients or
Guiding Therapy
There are no randomized clinical trials that demonstrate
measurement of ABI is effective in motivating asymptomatic
patients to comply with measures to reduce cardiovascular
risk. There is also no indication that serial measurement of the
ABI can be used to monitor treatment or guide treatment
approaches.
2.5.7. Recommendation for Exercise Electrocardiography
Class IIb
1. An exercise ECG may be considered for cardiovascu-
lar risk assessment in intermediate-risk asymptomaticadults (including sedentary adults considering starting
a vigorous exercise program), particularly when atten-
tion is paid to non-ECG markers such as exercise
capacity.296–298 (Level of Evidence: B)
Patients who are capable of exercising on a bicycle or
treadmill with a normal resting 12-lead ECG are connected to
a modified-torso 12-lead ECG and asked to exercise at
increasing levels of stress until exhaustion or other milestones
are met, such as a target heart rate or worrisome clinical
findings (eg, severe chest discomfort). Treadmill testing is
more commonly performed in the United States; a variety of
protocols are used during which both speed and grade are
gradually increased in stages. Ideal exercise times are about 8
to 12 minutes. Although the best known measurement is
change in ST-segment deviation during and after exercise,
other important prognostic measures are exercise capacity,
chronotropic response, heart rate recovery, and exercise-
induced arrhythmias.299
2.5.7.1. Association With Increased Risk and
Incremental Risk
Several specific findings on exercise testing are associ-
ated with subsequent mortality and cardiovascular events (Table
7).299 An AHA scientific statement has described in de-
tail exercise test risk predictors in asymptomatic adults.299
Although many clinicians typically think of the exercise test as
primarily a measure of ST-segment changes that may reflect
ischemia, evidence has demonstrated that the ST segment is a
weak marker for prevalent and incident CAD.300,301 In contrast,
non-ECG measures have emerged as stronger predictors of risk.
Probably the most powerful risk marker obtained during routine
exercise testing is exercise capacity; numerous investigators
have consistently found that depressed exercise capacity is
associated with increased cardiovascular risk.296,298,299,302–305 In a
very large primary care population, adding exercise variables to
clinical variables increased the C index from 0.75 to 0.83 for
prediction of all-cause mortality.306 Among healthy executives,
adding exercise variables to clinical variables increased the C
index from 0.73 to 0.76.307
Markers reflective of autonomic nervous system function
can predict major cardiovascular events, total mortality, and
sudden cardiac death.297,308–313 Failure of the heart rate to rise
appropriately during exercise has been termed chronotropic
incompetence and has been linked to adverse outcome
whether or not beta blockers are being taken.299,314,315 The fall
in heart rate immediately after exercise, also known as heart
rate recovery, is thought to reflect parasympathetic tone.316
Decreased heart rate recovery has been associated with death
or cardiac events in a number of populations, including those
that are entirely or primarily asymptomatic.307,309,310,313,317–319
Frequent ventricular ectopy during recovery, similarly
thought to reflect abnormalities of parasympathetic nervous
system function, are also independently associated with
long-term risk of mortality.309 The adjusted HR is 1.5 (95%
CI 1.1 to 1.9; P0.003).309
To synthesize the clinical importance of these measures, a
number of exercise test scoring schemes have been developed
and validated. Probably the best-known is the Duke Treadmill
Factor I
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 Score (DTS), which incorporates exercise capacity, ST-
segment changes, and exercise-induced angina.313,320,321 The
formula for the DTS is
exercise time  (4 	 angina index)
 (5 	 maximal ST-segment depression).
The DTS has been validated in a number of populations as
predictive of risk. Of note however, the only element of the
DTS that has been consistently associated with increased
risk has been exercise capacity.301,313 In both younger and
older adults, ST-segment changes and exercise-induced
angina have not consistently appeared as risk
Table 7. Sample of Longitudinal Studies Reporting the Independ
Asymptomatic Populations
Primary
Measurement(s)
First Author
(Year, Country) Type of Events
Follow-Up
(y)
Exercise capacity Gulati (2003,
US)296
All-cause
death
8.4
Exercise capacity Wei (1999,
US)298
CVD death and
all-cause
death
10
Exercise capacity
and heart rate
recovery
Adabag (2008,
US)297
Sudden death,
CHD death,
nonfatal
CHD, all-
cause death
7
Chronotropic
response and
heart rate
recovery
Jouven (2005,
France)310
Sudden death 23
Exercise
capacity, heart
rate recovery,
and ST-
segment
changes
Mora (2003,
US)318
CVD death and
all-cause
death
20
Exercise
capacity, heart
rate recovery,
and ST-
segment
changes
Aktas (2004,
US)307
All-cause
death
8
Exercise capacity Kodama (2009,
International)
305
All-cause
death and
CHD/CVD
events
1.1 to 26
bpm indicates beats per minute; CHD, coronary heart disease; CI, confidence
LRC, Lipid Research Clinics; MET, metabolic equivalent; MRFIT, Multiple Riskpredictors.301,313The DTS has been criticized for its failure to take into
account demographics and simple risk factors. A nomogram
based on simple demographics, easily obtained risk factors,
and standard exercise test findings was found to better
discriminate risk than the DTS (C index, 0.83 versus 0.73;
P0.001); the nomogram was also successfully validated in
an external cohort.306
2.5.7.2. Usefulness in Motivating Patients or
Guiding Therapy
No randomized trials have specifically addressed the role of
exercise testing in these 3 areas. There is also no direct
information on the role of the exercise test to monitor
dictive Value of Exercise Electrocardiography Measures in
Population
aracteristics
(No.)
Mean Age (y)
at Entry Main Findings: Adjusted HR
en with
ean FRS of 6
721)
52 Compared with 8 METs, HR 1.9
(95% CI 1.3 to 2.9) for 5 to 8
METs and 3.1 (95% CI 2.0 to 4.7)
for 5 METs
in preventive
edicine
inic25,714
44 For CVD death, HR 3.1 (95% CI 2.5
to 3.8); for all-cause death, HR 2.2
(95% CI 1.4 to 3.8); all in normal
weight; similar in overweight and
obese men
in MRFIT
udy (12 555)
46 For all-cause death, HR 0.85 (95% CI
0.7 to 0.9) for 8 min of Bruce
protocol compared with 6 min
HR 0.90 (95% CI 0.82 to 0.99) for
heart rate recovery 65 bpm 3
min after exercise compared with
50 bpm
in Paris civil
rvice (5713)
47 For chronotropic response 89 bpm;
HR 6.18 (95% CI 2.30 to 16.11;
P0.001); for heart rate recovery
25 bpm; HR 2.2 (95% CI 1.02 to
4.74; P0.04)
en in LRC
evalence
udy (2994)
46 For CVD death, exercise capacity
below median HR 2.0 (95% CI
1.29 to 3.25); heart rate recovery
below median HR 2.9 (95% CI
1.85 to 4.39); ST-segment
depression 1 mm, HR 1.0 (95%
CI 0.59 to 1.80); similar for all-
cause death
in preventive
edicine clinic
554)
57 For impaired exercise capacity,
HR 3.0 (95% CI 1.98 to 4.39;
P0.001); for abnormal HR
recovery 12 bpm 1 min
postexercise; HR 1.6 (95% CI 1.04
to 2.41; P0.03); not significant
for ST-segment depression
lthy men and
omen in
eta-analysis
02 980)
37 to 57 For all-cause mortality, 1-MET
increase; HR 0.87 (95% CI 0.84 to
0.90); for CHD/CVD
l; CVD, cardiovascular disease; FRS, Framingham Risk Score; HR, hazard ratio;
ntervention Trial; and US, United States.ent Pre
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 2.5.8. Recommendation for Stress Echocardiography
Class III: No Benefit
1. Stress echocardiography is not indicated for cardiovas-
cular risk assessment in low- or intermediate-risk
asymptomatic adults. (Exercise or pharmacologic
stress echocardiography is primarily used for its role in
advanced cardiac evaluation of symptoms suspected of
representing CHD and/or estimation of prognosis in
patients with known coronary artery disease or the
assessment of patients with known or suspected valvu-
lar heart disease.) (Level of Evidence: C)
2.5.8.1. General Description
Stress echocardiography can be performed with dynamic
forms of exercise, including treadmill and bicycle, as well as
with pharmacologic stress, most often using dobutamine. The
manifestations of ischemia on echocardiography include seg-
mental and global left ventricular dysfunction. The use of
echocardiography during treadmill testing is indicated for
those patients with an abnormal resting ECG, including
findings of left bundle-branch block, electronically paced
rhythm, and LVH, as well as for patients taking digoxin. The
diagnostic performance of the test is highly dependent on the
availability of skilled acquisition and interpretation of the
images and should be performed according to best prac-
tices.322 MPI with echocardiographic contrast agents has not
been widely used, and there are no currently approved agents
available in the United States, so this technique is not
addressed here.
The current guideline focuses on the use of tests and
procedures that may be employed for assessment of cardio-
vascular risk in the asymptomatic adult. In several sections of
this document the writing committee has also assessed the
evidence for applying conventional diagnostic testing with or
without imaging. It is important to realize the vast difference
in concepts between use of a diagnostic test, usually in the
symptomatic patient, to define a patient’s likelihood of
obstructive CAD compared with stratification of risk in an
asymptomatic patient to serve as a basis for cardiovascular
preventive strategies. Stress echocardiography is a test pre-
dominantly used in symptomatic patients to assist in the
diagnosis of obstructive CAD. There is very little information
in the literature on the use of stress echocardiography in
asymptomatic individuals for the purposes of cardiovascular
risk assessment. Accordingly, the Class III (LOE: C) recom-
mendation for stress echocardiography reflects a lack of
population evidence of this test for risk assessment purposes.
This contraindication to testing must be placed within the
concept of accepted indications for testing asymptomatic
patients for diagnosis of CAD, such as for asymptomatic
individuals undergoing preoperative risk assessment,323 pa-
tients with new-onset atrial fibrillation, or a clinical work-up
after episodes of ventricular tachycardia or syncope. In
contrast, the current guideline focuses on risk assessment in
the asymptomatic adult, which must not be confused with
evaluation of the patient without chest pain with ischemic
equivalents such as dyspnea, where in some cases, stress
testing may be considered appropriate. The focus of theselatter evaluations is to assess a patient’s ischemic burden and
the ensuing likelihood of obstructive CAD. There are clinical
practice guidelines and appropriate use criteria that focus on
the quality of evidence for assessment of asymptomatic
patients or those with ischemic equivalents and clinical
indications for the use of stress echocardiography. The
current guideline is not applicable in this setting of diagnosis
of CAD.
2.5.8.2. Association With Increased Risk
In a cohort of 1832 asymptomatic adults with no history of
CHD (mean age, 51 years; 51% male), the predictive value of
exercise echocardiography was examined at a mean of almost
5 years of follow-up.324 The incidence of significant ST-
segment depression was 12%, and the incidence of inducible
wall motion abnormalities was 8%. The presence of inducible
wall motion abnormalities was not an independent predictor
of cardiac events in the entire population or those with 2
risk factors.324 There are additional clinical studies in patients
with type 2 diabetes mellitus. One small series compared
screening with combined exercise electrocardiography and
dobutamine stress echocardiography to a no-screening strat-
egy in 141 patients with type 2 diabetes. The series found that
the screening strategy was associated with reduced cardiac
events when those with inducible wall motion abnormalities
(21%) underwent revascularization.325
No information is currently available to assess the role of
exercise echocardiography in addition to conventional risk
factors for risk assessment in asymptomatic adults. Because
of the lack of information on the role of risk assessment in the
asymptomatic adult, the writing committee thought that there
was no basis to recommend stress echocardiography for
routine risk assessment in this type of patient.
2.5.8.3. Usefulness in Motivating Patients or
Guiding Therapy
There have been no randomized trials on exercise echocardi-
ography to suggest that it can be used to motivate lifestyle
behavior changes in asymptomatic adults. One small pilot
trial in patients with type 2 diabetes is cited above.325 No
other trials have investigated the use of echocardiography to
guide therapy in asymptomatic adults. Thus, there is no clear
indication that an exercise echocardiogram can be used to
motivate asymptomatic adults or guide their therapy.
2.5.9. Myocardial Perfusion Imaging
2.5.9.1. Recommendations for Myocardial
Perfusion Imaging
Class IIb
1. Stress MPI may be considered for advanced cardiovas-
cular risk assessment in asymptomatic adults with
diabetes or asymptomatic adults with a strong family
history of CHD or when previous risk assessment
testing suggests high risk of CHD, such as a CAC score
of 400 or greater. (Level of Evidence: C)
Class III: No Benefit
1. Stress MPI is not indicated for cardiovascular risk
assessment in low- or intermediate-risk asymptomatic
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 adults. (Exercise or pharmacologic stress MPI is pri-
marily used and studied for its role in advanced
cardiac evaluation of symptoms suspected of repre-
senting CHD and/or estimation of prognosis in patients
with known CAD.).326 (Level of Evidence: C)
2.5.9.2. Description of Myocardial Perfusion Imaging
Exercise or pharmacologic stress MPI using single-photon
emission computed tomography (SPECT) or positron emis-
sion tomography (PET) is predominantly considered appro-
priate for the clinical evaluation of symptoms suggestive of
myocardial ischemia or for determination of prognosis in
patients with suspected or previously known CAD. As noted
in the stress echocardiography section, it is important to
recognize the distinction between the use of a diagnostic test
to define the likelihood of obstructive CAD in a symptomatic
patient and the possible role of a diagnostic test in risk
assessment of an asymptomatic individual, for whom the
results of testing would be used in decision making about
strategies for prevention of CVD. This guideline is not
intended to address the evaluation of patients presenting with
possible cardiovascular symptoms or signs such as dyspnea,
syncope, or arrhythmia, nor does this guideline address the
preoperative assessment of a high-risk patient. These patient
evaluations are the topics of other guidelines, and the reader
is referred to other guidelines when confronted with such
symptomatic patients.
Stress myocardial perfusion SPECT and PET involve
exposure to ionizing radiation. The effective radiation dose
for SPECT and PET considerably exceeds that of a CAC
score (median effective dose: 2.3 millisievert [mSv]), and
therefore the use of these modalities should be limited to
patients in whom clinical benefit exceeds the risk of radiation
exposure, for example, higher-risk or older patients. Use of
these procedures must be performed with the guiding princi-
ple of applying effective doses that are “as low as reasonably
achievable” (ie, ALARA). The estimated effective dose for
stress myocardial perfusion SPECT is 14.6 mSv, whereas
that of Rb82 PET is 5 mSv.327 For all patients, dose-
reduction strategies should be used whenever possible (eg,
stress-only imaging), and these approaches may reduce
SPECT doses to as low as 5 to 8 mSv.328 The clinician is
strongly urged to consider radiation exposure when deciding
whether the benefit of testing an asymptomatic patient out-
weighs the potential risks.
2.5.9.3. Evidence of Association With Increased
Cardiovascular Risk in Asymptomatic Adults
There are few studies on the role of stress MPI for risk
assessment in asymptomatic persons. The writing committee
did not identify any studies in population-based (relatively
unselected) asymptomatic individuals. Reported studies of
stress perfusion imaging in asymptomatic persons have in-
volved selected higher-risk patients who were referred for
cardiac risk evaluation. In 1 large series of patients referred to
a stress perfusion imaging laboratory (n3664 asymptomatic
patients), those with 7.5% myocardial ischemia had an
annual event rate of 3.2%, which was consistent with high
risk. High-risk findings were noted in10% of asymptomatic
patients who were referred. Limitations of the study includethe absence of clear indications for referral and absence of
prior global risk assessment as a basis for advanced risk
assessment.329 A second study, from the Mayo Clinic, se-
lected 260 asymptomatic patients from a nuclear cardiology
database (678 years, 72% male) without known CAD who
were at moderate risk for CHD by FRS.330 SPECT MPI
images were categorized using the summed stress score.
Mean follow-up was nearly 10 years. Abnormal SPECT MPI
scans were present in 142 patients (55%). By summed stress
score categories, SPECT scans were low risk in 67% of
patients, intermediate risk in 20%, and high risk in 13%.
Survival was 60% for patients with high-risk scans (95% CI
45% to 80%), 79% with intermediate-risk scans (95% CI 69%
to 91%), and 83% with low-risk scans (95% CI 77% to 88%)
(P0.03), including 84% (95% CI 77% to 91%) with normal
scans. In asymptomatic intermediate- to higher-risk patients,
these available data suggest a possible role for stress perfu-
sion imaging in advanced risk assessment of selected asymp-
tomatic patients.
Risk stratification using MPI has also been studied in
asymptomatic patients with diabetes.331–337 In 1 multicenter
study of 370 asymptomatic persons with diabetes recruited
from departments of diabetology,335 abnormality was defined
as a fixed or reversible perfusion defect or a positive stress
ECG. These abnormalities (compared with patients with
normal study results) were associated with a 2.9-fold (1.3 to
6.4) higher risk for cardiovascular events in patients 60
years of age but not for those 60 years of age. In the DIAD
(Detection of Ischemia in Asymptomatic Diabetics) trial,
asymptomatic, relatively low-risk patients with diabetes were
randomized to screening for “silent” myocardial ischemia
using adenosine stress MPI as an initial screening test versus
“usual care”.337 The DIAD study found evidence of effective
risk stratification, with annual cardiovascular event rates of
0.4% for those with normal- or low-risk scans compared with
2.4% for those with a moderate to large perfusion defect
(P0.001).337 However, the overall result of the DIAD study
was no significant difference in clinical outcomes in the
screened group versus the usual care group (see further on
this point below).
Stress perfusion imaging tests have been studied in a
limited way when used as a secondary test following an initial
evaluation with exercise ECG, carotid IMT, or
CAC.333,338–343 A summary of the literature from the ASNC
synthesized published reports in patients who had these
first-level indications of higher risk. Results suggested that as
many as 1 in 3 of higher-risk patients with a CAC score of
400 had demonstrable ischemia. The prevalence of isch-
emia can be quite high in patients with diabetes, especially
those with a family history of CHD.340,344 In a series of 510
asymptomatic patients with type 2 diabetes recruited from 4
London diabetes clinics, the incidence of myocardial isch-
emia was 0%, 18.4%, 22.9%, 48.3%, and 71.4% for those
with CAC scores of 0 to 10, 11 to 100, 101 to 400, 401 to
1000, and 1000, respectively (P0.0001).
Three studies have reported the prognosis for patients
referred to either initial CAC screening or combined CAC
scanning with stress MPI.333,341,343 In 1 series that included a
mixed sample of asymptomatic patients and patients with
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 chest pain, high-risk CAC scores did not confer an elevated
cardiovascular event risk. In another series of 621 patients
who underwent hybrid PET-CT imaging with CAC scoring,
one third of whom were asymptomatic, cardiovascular event-
free survival was worse for patients with ischemia on PET
plus a CAC score 1000 (P0.001). In another study using
a patient registry, data on asymptomatic patients with type 2
diabetes were reported.333 The inclusion criteria for the latter
prospective registry included patients with diabetes who were
50 years of age with either prior carotid IMT 1.1 mm,
urinary albumin rate 30 mg/g creatinine, or 2 of the
following: abdominal obesity, HDL cholesterol 40 mg/dL,
triglycerides150 mg/dL, or hypertension130/85 mm Hg.
One-year event-free survival ranged from 96% to 76% for
those with a summed stress score ranging from 4 to 14
(P0.0001). These results suggest that stress perfusion im-
aging may have a role in the advanced testing of asymptom-
atic patients who have been evaluated with other modalities
and found to be at high risk of silent ischemia. Such patients
might include patients with a high-risk CAC score of400 or
higher-risk patients with diabetes, including those with a
strong family history of CHD.
2.5.9.4. Usefulness in Motivating Patients or
Guiding Therapy
There are limited data to demonstrate that stress-induced
evidence of silent ischemia in asymptomatic patients will
have an impact on patient management. These data are
limited to the use of follow-up testing in the DIAD trial.
Patients enrolled in the DIAD trial who were randomized to
screening with stress MPI had a higher rate of follow-up
coronary angiography and revascularization. These data are
consistent with single-center studies that have shown that
demonstration of high-risk myocardial perfusion scans in
asymptomatic patients with diabetes leads to diagnostic
cardiac catheterization to identify high-risk anatomy (eg,
3-vessel CAD or left main CAD) with a view toward
revascularization.345,346 One nonrandomized observational
study showed that asymptomatic patients with diabetes with
high-risk stress MPI scans had a better outcome with revas-
cularization than medical therapy.347
2.5.9.5. Changes in Patient Outcomes
There is evidence from 1 randomized trial on the utility of
stress MPI to screen for CVD in persons with diabetes.337 The
DIAD trial randomized 1123 patients to no screening com-
pared with screening with adenosine stress MPI. The trial
results revealed that stress MPI performed as an initial
screening test had no impact on 5-year outcomes compared
with nonscreening or usual care of asymptomatic patients
with diabetes.337 The relative hazard was 0.88 (95% CI 0.44
to 1.88) for those who were screened with stress myocardial
perfusion SPECT compared with those who were not
screened (P0.73). Notable limitations to this trial are its
small, underpowered sample size, the high crossover rate
(n170/562 nonscreening arm undergoing nonprotocol stress
testing), and the high incomplete follow-up rate (n81/1123)
exceeding the 49 observed cardiovascular events. Impor-
tantly, the enrolled patients were low risk with an annualcardiovascular event rate of 0.6% and included patients with a
normal resting 12-lead ECG.
2.5.10. Computed Tomography for Coronary Calcium
2.5.10.1. Recommendations for Calcium Scoring Methods
(see Section 2.6.1)
Class IIa
1. Measurement of CAC is reasonable for cardiovascular
risk assessment in asymptomatic adults at intermediate
risk (10% to 20% 10-year risk).18,348 (Level of Evi-
dence: B)
Class IIb
1. Measurement of CAC may be reasonable for cardio-
vascular risk assessment in persons at low to interme-
diate risk (6% to 10% 10-year risk).348–350 (Level of
Evidence: B)
Class III: No Benefit
1. Persons at low risk (<6% 10-year risk) should not
undergo CAC measurement for cardiovascular risk
assessment.18,348,351 (Level of Evidence: B)
2.5.10.2. Calcium Scoring Methods
Cardiac CT, using either multidetector row CT or electron
beam tomography, enables the acquisition of thin slices of the
heart and coronary arteries gated to diastole to minimize
coronary motion. Both are sensitive noninvasive techniques
that can detect and quantify coronary calcium, a marker of
atherosclerosis.352,353 The test is typically performed in a
prospectively ECG-triggered scanning mode with 2.5- to
3.0-mm thick axial images obtained through the heart. The
quantity of calcium within the coronary arteries is typically
scored as the area affected on the scan, multiplied by a
weighting factor depending on the Hounsfield unit density of
the calcium deposits.352 The radiation dose in a prospectively
triggered acquisition is low, with a typical effective dose of
1.5 mSv.354 Due to the radiation exposure and general low
prevalence of calcification in men 40 years of age and
women 50 years of age, patient selection is an important
consideration. CT scanning should generally not be done in
men40 years old and women50 years old due to the very
low prevalence of detectable calcium in these age groups.
The widespread use of CCTA has also raised concerns
about radiation dose for patients. The National Council on
Radiation Protection Report No. 160 stated that radiation
exposure to the U.S. population due to medical sources
increased 7 times between 1986 and 2006.355 CT calcium
scoring produces the same amount of radiation as 1 to 2
mammograms performed on each breast.356 The radiation
dose in a prospectively triggered acquisition is low, with a
typical effective dose of 0.9 to 1.1 mSv,354,357 but doses can be
higher if retrospective imaging is used.358 All current recom-
mendations suggest prospective triggering be used for CAC
scoring. CT personnel must be constantly aware of the risks
of radiation and strive to apply the lowest dose to the patient
consistent with the clinical study. Because of radiation
exposure and the general low prevalence of calcification in
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 men 40 years of age and women 50 years of age, CT
scanning should generally not be done in these younger-age
patients.
2.5.10.3. Data on Independent Relationship to
Cardiovascular Events
The majority of published studies have reported that the
total amount of coronary calcium (usually expressed as the
Agatston score) provides information about future CAD
events over and above the information provided by stan-
dard risk factors. Intermediate-risk patients with an ele-
vated CAC score (intermediate FRS and CAC 300) had
a 2.8% annual rate of cardiac death or MI (roughly
equivalent to a 10-year rate of 28%) that would be
considered high risk.352 Pooled data from 6 studies of
27,622 asymptomatic patients were summarized in an
ACCF/AHA clinical expert consensus document that ex-
amined predictors of the 395 CHD deaths or MIs.359 The
11,815 subjects who had CAC scores of 0 had a low rate
of events over the subsequent 3 to 5 years (0.4%, based on
49 events). Compared with a CAC score of 0, a CAC score
between 100 and 400 indicated a RR of 4.3 (95% CI 3.5 to
5.2; P0.0001), a score of 400 to 1000 indicated a RR of
7.2 (95% CI 5.2 to 9.9; P0.0001), and a score 1000
indicated a RR of 10.8 (95% CI 4.2 to 27.7; P0.0001).
The corresponding pooled rates of 3- to 5-year CHD death
or MI rates were 4.6% (for scores from 400 to 1000) and
7.1% (for scores 1000), resulting in a RR ratio of 7.2
(95% CI 5.2 to 9.9; P0.001) and 10.8 (95% CI 4.2 to
27.7; P0.0001).
Since the ACCF/AHA expert consensus document was
published, other prospective confirmatory studies have been
published.18,348,351,353,354 These studies have demonstrated
that the relationships between CAC outcomes are similar in
men and women and different ethnic groups.353,354 Each of
these studies demonstrated that the AUC to predict coronary
artery events is significantly higher with CAC than either
Framingham or PROCAM (Münster Heart Study) risk strat-
ification alone. In MESA, the C statistic with traditional risk
factors was 0.79 for major coronary events in the risk factor
prediction model and 0.83 in the risk factor plus CAC model
(P0.006).18
2.5.10.4. Usefulness in Motivating Patients
To understand the clinical utility of CAC testing as a risk
assessment tool, it is imperative to demonstrate that it alters
clinical management (such as the use of preventive medica-
tions). In an observational survey study, Kalia et al. showed
that self-reported lipid-lowering medication provision in-
creased from 44% over 3 years to 90% in those with
baseline calcium scores in the top 75th percentile for age and
sex (P0.001).360 This finding was independent of underly-
ing cardiovascular risk factors, age, and sex. Other cardio-
vascular risk behaviors were reported to be beneficially
affected, specifically showing that higher baseline CAC was
strongly associated with initiation of aspirin therapy, dietary
changes, and increased exercise.361
A randomized controlled study suggested that although a
calcium scan did not in itself improve net population healthy
behaviors, the post-test recurring interactions with a health-care provider can be useful to reinforce lifestyle and treatment
recommendations that could ensue from calcium testing.362
2.5.10.5. Use as a Repeat Measure to Monitor Effects of
Therapy in Asymptomatic Persons
Coronary calcium progresses at typically 10% to 20% of the
baseline value per year, and among persons45 years of age,
approximately 7% per year of those without calcium develop
detectable coronary calcium. The value of repeat calcium
scanning is governed by the interscan interval, rate of
coronary calcium progression, variability in repeated mea-
surements, and independent association to shifts in prognosis
and management based on the observed calcium progression
rate. Although preliminary data suggest that a calcium scan
progression rate of 15% per year is associated with a
17-fold increased risk for incident CHD events,363 there are
no data demonstrating that serial CAC testing leads to
improved outcomes or changes in therapeutic decision
making.354
2.5.10.6. Usefulness of Coronary Calcium Scoring in
Guiding Therapy
Calcium scores 100 to 300 are associated with a high rate
of incident CHD events over the ensuing 3 to 5 years, so that
persons with calcium scores in this range are a suitable target
group for stringent lifestyle recommendations, selection of
evidence-based therapeutic agents to reduce cardiovascular
risk, and focus on adherence to medical recommendations. In
the Prospective Army Coronary Calcium study, among 1640
participants followed up for 6 years, use of statin and aspirin
was independently 3.5- and 3-fold greater in those with any
coronary calcium over 6 years, suggesting management
changes can occur following calcium screening in
community-based cohorts.364 Multiple logistic regression
analysis, controlling for National Cholesterol Education Pro-
gram (NCEP) risk variables, showed that CAC was indepen-
dently associated with a significantly higher likelihood of use
of statin, aspirin, or both (OR 6.97; 95% CI 4.81 to 10.10;
P0.001).364 The OR for aspirin and statin use based on
NCEP risk factors alone was dramatically lower (OR 1.52;
95% CI 1.27 to 1.82; P0.001). Recent data from MESA
suggest similar effects of CAC visualization on lipid-lowering
and aspirin therapy.365
2.5.10.7. Evidence for Improved Net Health Outcomes
Evidence is not available to show that risk assessment using
CAC scoring improves clinical outcomes by reducing mor-
tality or morbidity from CAD.
2.5.10.8. Special Considerations
2.5.10.8.1. Coronary Calcium Scoring in Women. A vast
majority of women 75 years of age are classified by FRS to
be low risk. In 1 study of 2447 consecutive asymptomatic
women without diabetes (5510 years), 90% were classified
as low risk by FRS (9%), 10% as intermediate risk (10% to
20%), and none had a high-risk FRS 20%.366 CAC was
observed in 33%, whereas moderate (CAC 100), a marker
of high risk, was seen in 10% of women. Overall, 20% of
women had CAC 75th percentile for age and gender,
another marker for future CHD events. However, when FRS
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 was used, the majority (84%) of these women with significant
subclinical atherosclerosis 75th percentile were classified
as low risk, whereas only 16% were considered intermediate
risk. Thus, FRS frequently classifies women as being low
risk, even in the presence of significant CAC. Based on this
1 substudy from MESA, it is possible that CAC scoring may
provide incremental value to FRS in identifying which
asymptomatic women may benefit from targeted preventive
measures.349 A recent report noted net reclassification im-
provement with CAC in relation to risk factors for all-cause
mortality in women 60 years of age.367 In terms of the
overall predictive capacity of high calcium scores, several
studies have demonstrated that CAC-associated outcomes are
similar in men and women.368,369
For a discussion of the utility of CAC testing in persons
with diabetes, see Section 2.6.1.
2.5.10.8.2. Comparison of Coronary Artery Calcium Scoring
with Other Risk Assessment Modalities. Several studies have
compared multiple techniques for cardiovascular risk strati-
fication.350,369–371 Four studies comparing the predictive abil-
ities of hsCRP with CAC have demonstrated that CAC
remains an independent predictor of cardiovascular events in
multivariable models, whereas CRP no longer retains a
significant association with incident CHD.350,369–371 This has
recently been confirmed in MESA as well.18,351 The CAC
score was also shown to be a better predictor of subsequent
CVD events than carotid IMT. Multivariable analysis re-
vealed HRs for CHD of 1.7 (95% CI 1.1 to 2.7; P0.07) for
carotid IMT and 8.2 (95% CI 4.5 to 15.1; P0.001) for CAC
score (quartile 4 versus quartiles 1 and 2).252
2.5.11. Coronary Computed Tomography Angiography
2.5.11.1. Recommendation for Coronary Computed
Tomography Angiography
Class III: No Benefit
1. Coronary computed tomography angiography is not
recommended for cardiovascular risk assessment in
asymptomatic adults.372 (Level of Evidence: C)
2.5.11.2. General Description
CCTA has been widely available since around 2004, when
64-detector scanners were produced by multiple vendors.
Two basic scanning protocols may be used; both require ECG
monitoring and gating. Helical (or spiral) scanning uses
continuous image acquisition while the patient moves slowly
through the scanner plane. Axial scanning incorporates a
scanning period, followed by a patient movement period,
followed by another scanning period (step-and-shoot). Com-
pared with invasive coronary angiography using a cine
system, both the temporal and spatial resolution of CCTA are
far less (spatial: 200 microns versus 400; temporal: 10 ms
versus approximately 80 to 190 ms, depending on the type of
scanner). CCTA provides the best quality images when the
heart rate is regular and slow (60 bpm if possible).
CCTA has been compared with invasive coronary angiog-
raphy for detection of atherosclerosis (typically defined as a
50% diameter stenosis).373 Sensitivities and specificities from40 studies are consistently in the range of 85% to 95%, and
the most important test feature is the high negative predictive
value (98%).373 In addition, CCTA can image mild plaque
(50%) in the vessel wall. Plaques may be roughly charac-
terized according to their density (Hounsfield units) as calci-
fied or noncalcified. CCTA requires a CT scanner with at
least 64 detector rows and specialized software (approximate
cost, $1 million). Concern has been raised that CCTA uses
ionizing radiation. CCTA studies using unmodulated, helical
scanning deliver 12 to 24 mSv of radiation per examina-
tion.373 Methods to reduce the radiation dose, including ECG
dose modulation or prospective ECG-triggered axial scan-
ning, have resulted in doses of less than 3 mSv in selected
patients (estimated radiation dose associated with CCTA).374
2.5.11.3. Association With Increased Risk and Incremental
Prediction in Asymptomatic Persons
Very limited information is available on the role of CCTA for
risk assessment in asymptomatic persons. In a study from
Korea, 1000 middle-aged patients underwent CCTA as a
component of a general health evaluation.372 Patients were
either self-referred to this examination or referred by a
physician. Patients with chest discomfort or known CAD
were excluded from the analysis. Clinical follow-up was
obtained at 172 months in 97% of patients. Coronary
calcium was detected in 18% of patients, and 22% had
identifiable atherosclerotic plaque. Significant (50%) steno-
ses were found in 5% of patients. CCTA results were
compared with the NCEP ATP III risk classification. The
majority of patients were classified as low risk (55.7%) by
NCEP criteria. Only 10.2% were classified as high risk. The
prevalence of significant coronary stenoses in the low-,
moderate- and high-risk groups was 2%, 7%, and 16%,
respectively. During follow-up, 15 patients had “cardiac
events,” although 14 of these were revascularization proce-
dures prompted by the CCTA results. There were no deaths or
MIs. Additional diagnostic testing was performed in 14% of
patients identified as having coronary atherosclerosis, repre-
senting 3.1% of the entire screened population. On the basis
of the small number of nonprocedural events in this study, the
authors could not compare CCTA results with the NCEP risk
assessment data for risk prediction purposes. No other studies
have been reported to date on the potential utility of CCTA
results for risk assessment in asymptomatic adults with
coronary events as the outcome.
2.5.11.4. Changes in Patient Outcomes
There are no published trials evaluating the impact of specific
therapy on clinical outcome in patients identified as having
noncalcified atheroma by CCTA.
2.5.12. Magnetic Resonance Imaging of Plaque
2.5.12.1. Recommendation for Magnetic Resonance
Imaging of Plaque
Class III: No Benefit
1. MRI for detection of vascular plaque is not recom-
mended for cardiovascular risk assessment in asymp-
tomatic adults. (Level of Evidence: C)
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 2.5.12.2. General Description
MRI is a noninvasive method of plaque measurement that
does not involve ionizing radiation. Studies of the aorta and
the femoral and carotid arteries have demonstrated the capa-
bility of MRI for detection and quantification of atheroscle-
rosis and suggested its potential for risk assessment and
evaluation of the response to treatment in asymptomatic
patients. MRI seems to offer the greatest role for plaque
characterization as distinct from lesion quantification. Exam-
ination of plaque under different contrast weighting (black
blood: T1, T2, proton density-weightings, and magnetization
prepared rapid gradient echocardiography or bright blood:
time of flight) allows characterization of individual plaque
components,375,376 including lipid-rich necrotic core,377 fi-
brous cap status,378 hemorrhage,379,380 and calcifica-
tion.377,381,382 Although most magnetic resonance plaque im-
aging studies do not require exogenous contrast
administration, gadolinium-based contrast agents can further
improve delineation of individual plaque components such as
the fibrous cap and lipid-rich necrotic core.383,384
Several studies have demonstrated that MRI findings are
correlated with atherosclerosis risk factors. Aortic MRI scan-
ning in 318 patients participating in the Framingham Heart
Study found that after age adjustment, plaque prevalence and
burden correlated with FRS for both women and men.385 In
another Framingham Heart Study, subclinical aortic athero-
sclerosis was seen in nearly half of subjects and increased
with advancing age. Hypertension was associated with in-
creased aortic plaque burden. In the MESA study, aortic wall
thickness measured with MRI increased with age, but males
and blacks had the greatest wall thickness.386 In another
MESA study, it was found that thickened carotid walls and
plasma total cholesterol, but not other established CHD risk
factors, were strongly associated with lipid core presence by
MRI.387
A few small prospective studies have been done to inves-
tigate characteristics of carotid artery plaque on MRI that are
associated with disease progression and future cardiovascular
events. One study examined patients with symptomatic and
asymptomatic carotid disease to determine whether fibrous
cap thinning or rupture as identified on MRI were associated
with a history of recent transient ischemic attack or stroke.
When compared with patients with a thick fibrous cap,
patients with a ruptured cap were 23 times more likely to have
had a recent transient ischemic attack or stroke.388 In a
separate study of symptomatic carotid disease, patients with
lipid cores in carotid plaque by MRI had ipsilateral cerebral
infarctions more often than those without lipid cores (68%
versus 31%; P0.03).389 Another study performed carotid
MRI on 53 patients within 7 days of a second cerebrovascular
accident. Patients with “vulnerable” carotid lesions, as de-
fined by eccentric shape and heterogeneous signal on MRI,
had an 8 times greater risk of a third cerebrovascular accident
compared with those without vulnerable lesions (24% versus
3%; P0.023).390
Prospective studies demonstrated that hemorrhage within
carotid atherosclerotic plaques was associated with an accel-
erated increase in subsequent plaque volume over a period of
18 months.391 An increased risk of ipsilateral cerebrovascularevents has also been reported over a mean follow-up period of
38.2 months in asymptomatic patients who had 50% to 79%
carotid stenosis and the presence of a thin or ruptured fibrous
cap, intraplaque hemorrhage, or a larger lipid-rich necrotic
core.392 These studies support the hypothesis that the pres-
ence of intraplaque hemorrhage is a potent atherogenic
stimulus.
At this time there are no published prospective population
data to evaluate the role of MRI findings in risk assessment of
asymptomatic adults. A number of large-scale studies are
ongoing. It is recommended that additional large-scale mul-
ticenter trials be conducted to evaluate the possibility of using
MRI in the detection of atherosclerosis in asymptomatic
patients.
Rapid technological progress is transforming the imaging
of atherosclerotic CVD at the molecular level using nanopar-
ticles.393 In addition, a new generation of hybrid technology is
now becoming available; this technology combines multiple
imaging modalities, including PET in a single platform (eg,
PET/CT and MR/PET), using 1 machine for 1 type of
imaging to measure atherosclerotic plaque metabolic activity
with anatomical special resolution and contrast.394–396 There
is no information available yet on the role of these newer tests
for risk assessment in the asymptomatic adult.
2.6. Special Circumstances and Other
Considerations
2.6.1. Diabetes Mellitus
2.6.1.1. Recommendations for Patients With Diabetes
Class IIa
1. In asymptomatic adults with diabetes, 40 years of age
and older, measurement of CAC is reasonable for
cardiovascular risk assessment.344,397–399 (Level of Evi-
dence: B)
Class IIb
1. Measurement of HbA1C may be considered for car-
diovascular risk assessment in asymptomatic adults
with diabetes.400 (Level of Evidence: B)
2. Stress MPI may be considered for advanced cardiovas-
cular risk assessment in asymptomatic adults with
diabetes or when previous risk assessment testing
suggests a high risk of CHD, such as a CAC score of
400 or greater. (Level of Evidence: C)
2.6.1.2. General Description and Background
CVD is the major cause of morbidity, mortality, and health-
care costs for patients with diabetes.401 Compared with the
general population, patients with diabetes have a 4 times
greater incidence of CHD402 and a 2- to 4-fold higher risk of
a cardiovascular event.307 The risk of MI in patients with
diabetes without prior documented CHD is similar to the risk
of reinfarction in patients without diabetes with known
CHD.403 Women with type 2 diabetes are particularly prone
to developing cardiovascular complications (the age-adjusted
risk ratio of developing clinical CHD among people with
diabetes was 2.4 in men and 5.1 in women compared with
patients without diabetes).403
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 The prevalence of significant coronary atherosclerosis in a
truly representative population of patients with type 2 diabe-
tes has not been ascertained. One estimate is that 20% of
patients with diabetes have coronary atherosclerosis.404 How-
ever, in an asymptomatic and uncomplicated cohort of
patients with type 2 diabetes, 46.3% had evidence of coronary
artery calcification reflective of coronary atherosclerosis.344
The prevalence of CAD on multislice CT was 80% in a group
of 70 asymptomatic patients with type 2 diabetes.399 The
majority of these patients had diffuse involvement of all 3
coronary arteries. In another study by this group, 60% of
asymptomatic patients with diabetes had evidence of coro-
nary calcification, of which 18% had calcium scores of
400.405 Seventy percent had coronary luminal narrowing of
1 or more coronary arteries on multislice CT coronary
angiography, patients with diabetes showed more plaques on
multislice CT than patients without diabetes (7.13.2 versus
4.93.2; P0.01) with more calcified plaques (52% versus
24%).406 On invasive grayscale intravascular ultrasound,
patients with diabetes in this study had a larger plaque burden
(48.7%10.7% versus 40.0%12.1%; P0.03). Asymptom-
atic patients with diabetes have more coronary calcification
than patients without diabetes even when controlling for other
variables,407–409 and for every increase in CAC on CT scan-
ning, mortality for patients with diabetes is higher than in
patients without diabetes.407 However, patients with diabetes
with no coronary calcium have a survival rate similar to that
of subjects without diabetes and with no identifiable coronary
calcium.407 The overall rate of death or MI was 0%, 2.6%,
13.3%, and 17.9% (P0.0001) in patients with diabetes with
a CAC score of 100, 100 to 400, 401 to 1000 and 1000,
respectively.344 ROC curve analysis showed by AUC that the
CAC (AUC: 0.92; 95% CI 0.87 to 0.96) was superior to the
UKPDS (United Kingdom Prospective Diabetes Study Risk
Score) (AUC, 0.74; 95% CI 0.65 to 0.83) and FRS (AUC,
0.60; 95% CI 0.48 to 0.73; P0.0001) for predicting cardiac
events, with a risk ratio of 10.1 (95% CI 1.68 to 61.12) for
patients with a score of 100 to 400 and 58.1 (95% CI 12.28
to 100) for scores 1000.344
The CAC score has been found to be predictive beyond
conventional risk factors in several studies in patients with
diabetes. In the PREDICT (Patients with Renal Impairment
and Diabetes Undergoing Computed Tomography) study, 589
patients with type 2 diabetes underwent CAC measure-
ment.398 At a median of 4 years’ follow-up, in a predictive
model that included CAC score and traditional risk factors,
the CAC score was a highly significant independent predictor
of CHD events or stroke. The model found that a doubling in
calcium score was associated with a 32% increase in risk of
events (29% after adjustment). Only the homeostasis model
assessment of insulin resistance predicted primary endpoints
independent of the CAC score. In another study, after
adjusting for CHD risk factors, the CAC score was signifi-
cantly associated with occurrence of coronary events in
patients without diabetes but not in patients with diabetes.410
Another study performed CAC measurement in 716 asymp-
tomatic patients with diabetes and no history of CHD .397
During 8 years of follow-up, 40 patients had MI and 36
additional patients experienced cardiac death. The CAC scorewas significantly higher in those with events compared with
those without events, 5.6% per year for patients with scores of
400 versus 0.7% per year for those with lower scores.397
The area under the ROC curve with CAC in the model was
significantly higher (0.77) for prediction of MI than the FRS
(0.63).
2.6.1.3. Electrocardiographic Stress Testing for Silent
Myocardial Ischemia (See Section 2.5.7)
The value of exercise ECG testing to detect silent ischemia
and assess prognosis has been evaluated in a few small
studies of asymptomatic patients with diabetes.411–416 ECG
stress testing has an approximate 50% sensitivity and 80%
specificity.401 The positive predictive value for detecting
CAD using coronary angiography as the gold standard ranges
between 60% and 94% and was higher in men than wom-
en.401,416 Recommendations for exercise stress testing for risk
assessment do not appear to be different in patients with
diabetes and patients without diabetes.
2.6.1.4. Noninvasive Stress Imaging for Detection of Isch-
emia and Risk Stratification (See Section 2.5.9)
The prevalence of asymptomatic ischemia as determined by
noninvasive imaging in patients with diabetes ranges from
16% to 59%345,346,417–419 and depends on the pretest clinical
risk of CAD in the population. The DIAD study337 was
composed of a group of patients with type 2 diabetes who
were at lower risk than those undergoing stress imaging in
other studies, with only 6% of the 522 patients manifesting
large defects on adenosine MPI. All had a normal resting
ECG, whereas in a separate Mayo Clinic cohort, 43% had
abnormal Q waves on the ECG and 28% had peripheral
vascular disease.346 Approximately 50% of the Mayo Clinic
study patients were referred for preoperative testing for risk
assessment. In another report from the same group, 58.6% of
asymptomatic patients with diabetes had an abnormal scan,
and 19.7% had a high-risk scan.345 In another retrospective
study, 39% of asymptomatic patients with diabetes had an
abnormal stress scan.419 Of those presenting with dyspnea,
51% had an abnormal perfusion study. The annual hard event
rate at follow-up (7.7%) was highest in those presenting with
dyspnea compared with 3.2% in those presenting with angina.
Using contrast dipyridamole echocardiography, approxi-
mately 60% of asymptomatic patients with diabetes who were
60 years of age had abnormal myocardial perfusion with
vasodilator stress.
Asymptomatic patients with diabetes who have high CAC
scores have a high prevalence of inducible ischemia on stress
imaging.339 In a prospective study, 48% of patients with
diabetes with a CAC score of 400 had silent ischemia on
SPECT imaging, and in those with a score of 1000, 71.4%
had inducible ischemia.344 The majority of the defects were
moderate to severe. Patients with diabetes with inducible
ischemia have a higher annual death or nonfatal infarction
rate compared with patients without diabetes with similar
perfusion abnormalities on stress imaging (10% versus
6%).420 Also, the greater the degree of ischemia, the worse the
outcome during follow-up in both asymptomatic and symp-
tomatic patients with diabetes.344,421 The risk ratio for cardiac
events was 12.27 (95% CI 3.44 to 43.71; P0.001) for
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 patients with 5% ischemic burden on stress SPECT.344
These observations should be tempered by the recent report
that 16% of patients with no coronary calcium had inducible
ischemia by rest-stress rubidium-82 PET imaging.343 The
prevalence of diabetes was 28% in that study. These data, in
aggregate, suggest that coronary calcium measurement in
patients with diabetes may justify different approaches to risk
assessment compared with patients without diabetes. The
writing committee therefore judged it reasonable to perform
coronary calcium measurement for cardiovascular risk as-
sessment in asymptomatic patients with diabetes who were
40 years of age.
2.6.1.5. Usefulness in Motivating Patients
To date there is no evidence that performing coronary
calcium imaging by CT scanning is effective in motivating
patients to better adhere to lifestyle changes, medical therapy
of diabetes, or primary prevention measures to reduce the risk
of developing coronary atherosclerosis or future ischemic
events.
2.6.1.6. Evidence of Value for Risk Assessment for Coronary
Atherosclerosis or Ischemia or Both to Guide Therapy or
Change Patient Outcomes
Because of the high risks associated with diabetes, diabetes
has been designated as a CHD risk equivalent by the NCEP.27
One study randomized 141 patients with type 2 diabetes
without known CAD to receive exercise ECG/dipyridamole
stress echocardiographic imaging or a control arm.325 If a test
result was abnormal, coronary angiography was performed
with subsequent revascularization as indicated by anatomic
findings. At a mean follow-up of 53.5 months, 1 major event
(MI) and 3 minor events (angina) occurred in the testing arm,
and 11 major and 4 minor events occurred in the control arm.
Numbers in the study were too small to be considered
definitive. In the DIAD study, 561 low-risk asymptomatic
patients were randomized to screening with adenosine
SPECT perfusion imaging; 562 patients were randomized to
no testing.337 All patients had a normal resting ECG and no
prior history of CAD. Over a mean follow-up of 4.8 years, the
cumulative event rate was 2.9% (0.6% per year), and there
was no difference in event rates between the 2 groups. In the
tested group, those with moderate or large defects had a
higher cardiac event rate than those with a normal scan or
small defects.337
2.6.1.7. Diabetes and Hemoglobin A1C
HbA1C is used to integrate average glycemic control over
several months and predict new-onset diabetes.156 A system-
atic review has suggested that HbA1C might be effective to
screen for the presence of diabetes.157 Some experts have
noted that screening with HbA1C might be advantageous
because it can be performed in nonfasting individuals.422 The
ADA now endorses the use of HbA1C to diagnose diabetes
and assess for future risk of diabetes in higher-risk
patients.158,423
2.6.1.8. Association With Cardiovascular Risk
Higher HbA1C concentrations have been associated with
elevated risk of CVD in asymptomatic persons with diabe-
tes.154 In a meta-analysis by Selvin et al, adjusted RRestimates for glycosylated hemoglobin (total glycosylated
hemoglobin, hemoglobin A1, or HbA1C levels) and CVD
events (CHD and stroke) were pooled by using random-
effects models.154 Three studies involved persons with type 1
diabetes (n1688), and 10 studies involved persons with type
2 diabetes (n7435). The pooled RR for CVD was 1.18; this
represented a 1% higher glycosylated hemoglobin level (95%
CI 1.10 to 1.26) in persons with type 2 diabetes. The results
in persons with type 1 diabetes were similar but had a wider
CI (pooled RR 1.15 [95% CI 0.92 to 1.43]). Important
concerns about the published studies included residual con-
founding, the possibility of publication bias, the small num-
ber of studies, and the heterogeneity of study results. The
authors concluded that, pending confirmation from large,
ongoing clinical trials, this analysis suggests that chronic
hyperglycemia is associated with an increased risk for CVD
in persons with diabetes.
2.6.1.9. Usefulness in Motivating Patients, Guiding Therapy,
and Improving Outcomes
It is unknown whether knowledge of HbA1C is associated
with better cardiovascular clinical outcomes in asymptomatic
patients with diabetes. In persons with established diabetes,
knowledge of HbA1C concentration was associated with
better understanding of diabetes care and glucose control.424
However, such knowledge was unaccompanied by objective
evidence of better clinical outcomes.424 It is unknown
whether HbA1C is useful for motivating persons without
diabetes.
Although the beneficial effects of glycemic control for
microvascular complications have been demonstrated by
numerous studies, the benefits for macrovascular complica-
tions, particularly CVD, remain controversial.425–427 Preven-
tion trials have demonstrated that persons with impaired
glucose tolerance have less progression to overt diabetes with
lifestyle and pharmacologic interventions but without accom-
panying reductions in CVD complications.428 A meta-
analysis of randomized controlled trials of persons with
diabetes reported that improved glycemic control was asso-
ciated with an improved IRR for macrovascular complica-
tions—mainly CVD—for both type 1 (IRR 0.38, 95% CI 0.26
to 0.56) and type 2 (IRR 0.81, 95% CI 0.73 to 0.91)
diabetes.429 However, the meta-analysis did not demonstrate a
reduction in cardiac events in persons with type 2 diabetes
(IRR 0.91, 95% CI 0.80 to 1.03).429
Recent large, randomized, controlled studies have also
failed to demonstrate that intensive blood glucose control and
a lower HbA1C level is accompanied by a reduction in
macrovascular events.430–432
2.6.2. Special Considerations: Women
The rationale for providing a separate section for risk assess-
ment considerations in women was based on reports of
underrepresentation of females within the published literature
and clinicians who considered women at lower risk when
their profiles were comparable to those of men. Moreover, the
focus on special considerations in testing women has been put
forward as a result of frequent reporting of underutilization of
diagnostic and preventive services and undertreatment in
women with known disease.433
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 2.6.2.1. Recommendations for Special Considerations
in Women
Class I
1. A global risk score should be obtained in all asymp-
tomatic women.22,434 (Level of Evidence: B)
2. Family history of CVD should be obtained for cardio-
vascular risk assessment in all asymptomatic women.22,55
(Level of Evidence: B)
2.6.2.2. Detection of Women at High Risk Using Traditional
Risk Factors and Scores
Nearly 80% of women 18 years of age have 1 or more
traditional CHD risk factors.435 Diabetes and hypertriglycer-
idemia are associated with increases in CHD mortality in
women more so than in men.436,437 In women, traditional and
novel risk factors are prevalent and frequently cluster (ie,
metabolic syndrome).438–440 CHD risk accelerates greatly for
women with multiple risk factors, and CHD risk notably
increases after menopause.
Global risk scores, such as the FRS, classify the majority of
women (90%) as low risk, with few assigned to high-risk
status before the age of 70 years.434,441 Several reports have
examined the prevalence of subclinical atherosclerosis in
female FRS subsets.349,366 In a recent study of 2447 women
without diabetes, 84% with significant coronary artery calci-
fication (75th percentile) were classified with a low FRS.366
The lack of sensitivity of FRS estimates in women was
presented in several reports, suggesting lower utility of FRS
in female patients.366,441 The Reynolds risk score in women
improved risk reclassification when compared with the FRS
by including hsCRP, HbA1C (if the patient has diabetes), and
family history of premature CHD.22 This finding has not been
uniformly confirmed in other studies that included women.
2.6.2.3. Comparable Evidence Base for Risk Stratification
of Women and Men
Within the past decade, high-quality, gender-specific evi-
dence in CHD risk stratification of women has emerged for
novel risk markers (eg, hsCRP) and cardiovascular imaging
modalities (eg, carotid IMT, CAC). This evidence reveals
effective and, importantly, similar risk stratification for
women and men as based on relatively large female cohorts
or a sizeable representation of females. Detailed discussions
and recommendations for each of the tests are provided in
Sections 2.4.2 for hsCRP, 2.5.1 for resting ECG, 2.5.3 for
carotid IMT, 2.5.6 for ABI, 2.5.7 for exercise ECG, and
2.5.10 for CAC. In the case of hsCRP, carotid IMT, ABI,
CAC, resting ECG, and exercise ECG, the recommendations
for men apply similarly to women. Limited female-specific
evidence is also available for FMD, thus warranting a Class
III, LOE B recommendation similar to that for men.
2.6.3. Ethnicity and Race
A variety of disparities exist in different ethnic groups with
respect to cardiovascular risk factors, incidence, and out-
comes.442 In 2002, age-adjusted death rates for diseases of the
heart were 30% higher among African Americans than
among whites of both sexes. Disparities were also common
with respect to the presence of atherosclerotic risk factors,with Hispanics and black women demonstrating the highest
rates of obesity. Blacks also had the highest rates for
hypertension, whereas hypercholesterolemia was highest
among white and Mexican-American males and white
women. Lower educational level and socioeconomic status
conferred a greater risk of dying from heart disease in all
ethnic groups.443
Minimal information is available at this time with regard to
differing risk assessment strategies in ethnic groups other than
whites. The writing committee did not find evidence to suggest
that ethnic groups other than whites should undergo selective
risk assessment approaches based on ethnicity.
2.6.4. Older Adults
Although increasing age is a risk factor for CVD, with
progression of age, the prevalence of traditional risk factors
also rises. Conceptually, risk intervention could be antici-
pated to have greater benefit at an elderly age, due to the
increased absolute risk for coronary events; however, age
comparisons for risk interventions have not been rigorously
tested. Furthermore, the term “elderly” is used to describe a
range of age subgroups from 65 to 74, 75 to 84, and 85
years in different studies. Elderly patients in the community
also vary substantially from those in clinical trials, with
greater comorbidity, renal dysfunction, traditional risk fac-
tors, etc, and with very limited data available for the oldest of
the old.
In the Cardiovascular Health Study, subclinical markers
(increased carotid IMT, decreased ABI, ECG, history of MI,
echocardiographic left ventricular dysfunction, coronary cal-
cium) predicted CVD events more than traditional risk scores.
The DTS does not predict cardiac survival beyond age 75,
with a 7-year cardiac survival for those classified as low,
intermediate, and high risk being 86%, 85%, and 69%,
respectively.444 Elderly patients have a more adverse progno-
sis than younger patients with the same Duke risk score.
Based on information drawn largely from the Cardiovascular
Health Study, application of traditional risk factors for risk
assessment in the elderly, as well as selected other tests, can
be considered an evidence-based approach.
2.6.5. Chronic Kidney Disease
Chronic kidney disease, the permanent loss of kidney func-
tion, is considered a coronary risk equivalent in various
observational studies. However, data are insufficient to define
differences in outcomes in populations with different degrees
of renal insufficiency versus normal renal function. Data for
lipid lowering with statins in the TNT (Treating to New
Targets) study, a population with documented CAD, suggest
serial improvement in renal function and clinical outcome,
but extrapolation to an asymptomatic healthy population is
inappropriate.445 Lipid lowering restricted to the elderly in the
PROSPER (Prospective Study of Pravastatin in the Elderly at
Risk) study failed to show benefit. Similarly, lipid lowering in
a dialysis population failed to show benefit.446 In TNT,
patients with diabetes with mild to moderate chronic kidney
disease demonstrated marked reduction in cardiovascular
events with intensive lipid lowering in contrast to previous
observations in patients with diabetes with end-stage renal
disease. It is important to note that TNT was not a study of
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 asymptomatic adults (the focus of this guideline) but rather
was focused on a CAD population.
3. Future Research Needs
3.1. Timing and Frequency of Follow-Up for
General Risk Assessment
There is little information available in the research literature
to suggest the optimal timing to initiate risk assessment in
adults. There is also limited information to inform decisions
about frequency of risk assessment in persons who are
determined to be at low or intermediate risk on initial risk
assessment. High-risk persons are likely to initiate treatment
strategies, and repeat risk assessment is likely to be a standard
component of patient follow-up. More research on the opti-
mal timing to begin risk assessment and repeat risk assess-
ment in the asymptomatic patient is warranted.
3.2. Other Test Strategies for Which Additional
Research Is Needed
3.2.1. Magnetic Resonance Imaging
Although MRI is an established cardiovascular imaging
modality, its use in risk assessment studies to date is very
limited. Research questions to be answered should focus on
1) which MRI parameters are the best for predicting major
macro- and microvascular disease in the asymptomatic pa-
tient, 2) whether such parameters add to existing risk scores,
and 3) what is the cost-effectiveness of such imaging accord-
ing to risk strata.
3.2.2. Genetic Testing and Genomics
At present the plethora of genetic tests available for assessing
cardiovascular risk has not reached the point of being able to
add to the general risk assessment approach using global risk
scoring with traditional risk factors and addition of careful
family history. Additional research on the role of genetic
testing, with specific attention to the value for incremental
risk prediction in asymptomatic people, is needed.
3.2.3. Geographic and Environmental or
Neighborhood Risks
Much research indicates that socioeconomic factors play a
role in cardiovascular risk. It remains unclear how this
information should best be measured and incorporated into
individual risk assessment or whether this area of research
applies primarily at the population and policy levels.
Attention to this area of research for individual risk
assessment was deemed to be warranted by the writing
committee.
3.2.4. Role of Risk Assessment Strategies in Modifying
Patient Outcomes
Although the concept of individual risk assessment as a
means of properly targeting intensity of risk treatments is
now engrained in the practice of medicine and cardiology,
data to support the clinical benefits of alternative testingstrategies are very limited. For example, would risk
assessments that use images of abnormal vessels be able to
motivate patients and achieve better patient outcomes than
testing strategies that use only historical information or
blood tests? Studies that evaluate the specific testing
strategy against a specific patient-centered outcome are
needed. In addition, comparative effectiveness of various
test strategies is needed to determine costs, benefits, and
comparative benefits of competing testing approaches.
3.3. Clinical Implications of Risk Assessment:
Concluding Comments
The assessment of risk for development of clinical manifes-
tations of atherosclerotic CVD is designed to aid the clinician
in informed decision making about lifestyle and pharmaco-
logic interventions to reduce such risk. Patients are broadly
categorized into low-, intermediate-, and high-risk subsets,
and level of intensity and type of treatments are based on
these differing assessments of risk.
The initial step in risk assessment in individual patients
involves the ascertainment of a global risk score (Framing-
ham, Reynolds, etc) and the elucidation of a family history of
atherosclerotic CVD. These Class I recommendations, which
are simple and inexpensive, determine subsequent strategies
to be undertaken. Persons at low risk do not require further
testing for risk assessment, as more intensive interventions
are considered unwarranted, and those already documented to
be at high risk (established CHD or coronary risk equivalents)
are already candidates for intensive preventive interventions,
so that added testing will not provide incremental benefit.
For the intermediate-risk patient, this guideline should help
the clinician select appropriate test modalities that can further
define risk status. Tests classified as Class IIa are those shown
to provide benefit that exceeds risk. Selection among these
will vary with local availability and expertise, decisions
regarding cost, and potential risks such as radiation exposure,
etc. Tests classified as Class IIb have less robust evidence for
benefit but may prove helpful in selected patients. Tests
classified as Class III are not recommended for use in that
there is no, or rather limited, evidence of their benefit in
incrementally adding to the assessment of risk; therefore,
these tests fail to contribute to changes in the clinical
approach to therapy. In addition, a number of Class III tests
discussed in this guideline require additional efforts to stan-
dardize the measurement or make the test more commonly
available on a routine clinical basis. Furthermore, some of the
Class III tests also pose potential harm (radiation exposure or
psychological distress in the absence of a defined treatment
strategy) and are therefore to be avoided for cardiovascular
risk assessment purposes in the asymptomatic adult. Until
additional research is accomplished to justify the addition of
Class III tests, the writing committee recommends against
their use for cardiovascular risk assessment.
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